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DNA of Tuberculosis (TB) bacteria were found in mam-
moth  bones  and  in  Egyptian  mummies  and  TB  has 
affected mankind since its appearance, despite many 
efforts to control and eliminate it [1]. 
It was already well known since the sanatoria period 
(Germany, 1857) when treatment against TB consisted 
of good food, rest, sun, and fresh air that about half 
of  TB  cases  recovered  almost  spontaneously.  Robert 
Koch’s  discovery  of  Mycobacterium  tuberculosis  in 
1882, Carlo Forlanini introduced the artificial pneumot-
horax in 1907 [1] and streptomycin was introduced at 
the  end  of  the  Second  World  War.  These  discoveries 
revolutionised the understanding and treatment of TB.
In spite of these discoveries, the epidemic trend has 
tended more towards an increase in recent years. The 
interventions  recommended  by  the  directly  observed 
treatment,  short-course  (DOTS)  and  the  Stop  TB 
Strategy introduced in 2006 [2], e.g. rapid diagnosis 
of  70%  of  existing  sputum  smear-positive  cases  and 
effective  treatment  of  85%  of  them,  are  very  power-
ful in reversing the epidemic trend. This was demon-
strated in several countries, e.g. in Peru and recently 
in Europe: Romania achieved 70/85% targets and, after 
an initial increase, was able to reduce both its case and 
case-fatality load [3].
Multidrug-resistant (MDR) and extensively drug-resist-
ant (XDR) TB mainly emerge as the result of misman-
agement  of  TB,  either  by  the  prescribing  physician 
(regimen, dose, duration) or the patient (compliance). 
Failure  of  the  programme  contributes  as  well:  poor 
quality drugs, lack of public health action in ensuring 
patient support and correcting early signs of sub-opti-
mal patient management represented by late sputum 
smear  and  culture  conversion,  presence  of  failures, 
defaulters and avoidable deaths.
As  underlined  by  the  joint  ECDC  and  World  Health 
Organization  Regional  Office  for  Europe  TB  report, 
launched on 18 March [11] the importance of good sur-
veillance to stem this trend cannot be underestimated. 
Where do we go with surveillance in Europe? Can we do 
more? How many MDR and XDR TB cases occur because 
of sub-optimal patient management?
This  issue  of  Eurosurveillance  casts  light  on  these 
important questions with four interesting articles [4-7].
A paper by Manissero et al. from the ECDC reports on sur-
veillance data in twenty-two countries of the European 
Union (EU) and European Economic Area (EEA) done by 
the ECDC Tuberculosis Programme [4]. Treatment out-
come monitoring was performed on culture-confirmed 
pulmonary TB cases reported in 2007. While the overall 
treatment success rate was 73.8% (79.5% among new 
cases), only three countries achieved the 85% success 
rate target as a result of high defaulting and a relevant 
proportion of unknown outcomes.
A surveillance report by Devaux et al. [5] describes ret-
rospectively the results of second-line drug suscepti-
bility testing (DST) among MDR TB cases reported in 
20  countries  of  the  WHO  European  Region  (15  being 
EU countries) aimed at identifying XDR TB. In 18 coun-
tries (only) DST was performed for two or more of the 
second-line drugs defining XDR TB, with relevant inter-
country variation on the proportion of isolated tested. 
Overall, 10% of the MDR TB strains are found to be XDR.
A report by Ködmön et al. [6] describes the surveillance 
data collected by ECDC from EU and EEA countries. In 
2008, the combined proportion of new and retreated 
MDR TB cases was 6.0% of the total case load for the 25 
countries reporting data. Thirteen countries provided 
data on resistance to second-line drugs, allowing the 
identification of XDR TB cases. 68 XDR TB cases were 
reported in 2007 (6.1% of the MDR TB cases) and 90 in 
2008 (7.3% of the MDR TB cases). Latvia and Romania 
notified the highest number of XDR TB cases in 2008.
Next is a surveillance report by Caley et al. on a retro-
spective cohort study performed in the UK to quantify 
the risk of developing TB infection or disease following 
school contact with an infectious student. The report 
results  suggest  that  greater  levels  of  classroom 3 www.eurosurveillance.org
contact with a sputum smear positive student signifi-
cantly increases the risk of contracting both active TB 
disease and latent TB infection.
The  results  of  the  studies  reported  in  this  issue  of 
Eurosurveillance allow us to point out some key topics:
•	   The completeness of reporting information (includ-
ing  treatment  outcomes),  the  proportion  of  cul-
ture-confirmed  TB  cases  reported  as  well  as  the 
proportion of strains on which DST for both first- 
and second-line drugs is performed and reported 
are  still  sub-optimal  overall  in  Europe.  The  rele-
vance of these pitfalls goes beyond the “simple” 
surveillance  limitation,  having  the  potential  to 
affect other important TB control pillars, e.g. infec-
tion control and case-management. 
•	   MDR and XDR TB still persist in Europe. The high 
proportion  of  MDR  TB  identified  among  new  TB 
cases reported by certain countries indicates that 
sub-optimal  infection  control  practices  are  likely 
to  occur,  while  the  high  percentage  of  MDR  TB 
notified among retreatment cases is probably the 
result of sub-optimal case management in the past 
decade. 
ECDC  is  managing  surveillance  of  TB  at  the  EU  level 
in  collaboration  with  national  correspondents,  WHO 
Regional  Office  for  Europe  and  partners.  The  joint 
ECDC  and  World  Health  Organization  Regional  Office 
for  Europe  TB  report,  launched  on  18  March,  shows 
that tuberculosis is still a matter of concern in Europe. 
Tuberculosis Surveillance in Europe 2008 presents the 
latest data on TB cases and shows that the decline in 
cases has slowed down [11]. 
With the enhanced and improved regular surveillance 
of anti-TB drugs and molecular surveillance of MDR TB 
cases, ECDC is offering an added value to the European 
surveillance [9,10]. Surveillance is an integral part of 
TB control, its contribution being essential to inform 
the programme on what is going on and what public 
health response is urgently needed. Investing in better 
“intelligence” is a pre-requisite to improve TB preven-
tion and control in Europe, in order to reach the elimi-
nation goal for Europe committed to in the early 1990s 
[8].
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Since  2008,  the  European  Centre  for  Disease 
Prevention and Control has been collecting data from 
the European Union (EU) and European Economic Area 
(EEA)  on  resistance  to  first-  and  second-line  drugs 
against tuberculosis (TB). In 2008, the proportion of 
multidrug-resistant  tuberculosis  (MDR  TB)  was  6.0% 
of the total case load for 25 countries reporting data. 
Extensively  drug-resistant  (XDR  TB)  reporting  has 
increased  since  2007  and  was  observed  in  7.3%  of 
the MDR TB cases in 13 reporting countries. MDR TB 
remains a threat and XDR TB is now established within 
the EU/EEA borders.
Background
Tuberculosis  (TB)  is  among  the  leading  causes  of 
death due to a single pathogen worldwide. The World 
Health  Organization  (WHO)  estimates  that  32%  of 
the  world  population  is  infected  with  Mycobacterium
tuberculosis, the causative agent of tuberculosis [1], with 
9.2 million new TB cases and 1.7 million deaths from TB 
reported in 2007 [2]. Drug resistance to isoniazid and 
rifampicin (the definition for multidrug-resistant (MDR) 
TB), the two most potent first-line antimicrobial drugs 
for the treatment of TB, is a persisting global problem 
with surveillance data indicating increasing trends in 
several countries [3–7]. In 2007, the WHO reported the 
highest rates of MDR TB ever recorded, with up to 22% 
of new TB cases being resistant to both isoniazid and 
rifampicin in some areas of the former Soviet Union [2]. 
The increases in prevalence and incidence of MDR TB 
are caused by concurrent factors such as inadequate 
treatment  regimens,  poor  case  holding,  suboptimal 
drug quality and transmission of resistant strains [8]. 
In  recent  years,  public  health  awareness  about  MDR 
TB  has  been  reinforced  by  the  occurrence  of  exten-
sively  drug-resistant  (XDR)  TB  outbreaks  associated 
with  human  immunodeficiency  virus  (HIV)  infections, 
particularly in South Africa [9,10]. XDR TB strains are 
defined as strains resistant to isoniazid and rifampicin 
(i.e. MDR) as well as to a fluoroquinolone and to one 
or  more  of  the  following  injectable  drugs:  amikacin, 
capreomycin, or kanamycin). 
In Europe, the prevalence of MDR TB is high, particu-
larly in some areas [4], and past surveillance reports 
have highlighted that MDR TB and XDR TB are a threat 
to TB control and elimination, also within the borders 
of the Member States of the European Union (EU) and 
European  Economic  Area  (EEA)  [11,12].  We  therefore 
aimed at analysing the most recent data for the EU and 
EEA to describe the current MDR/XDR TB situation in 
this region. 
Methods
Surveillance of drug resistance, based on annual case-
based  reporting  of  drug  susceptibility  testing  (DST) 
results, has been ongoing in Europe since 1998 through 
the EURO-TB network and has included annual report-
ing  of  MDR  TB  cases  [13].  Since  2008,  the  European 
Centre for Disease Prevention and Control (ECDC) and 
the WHO Regional Office for Europe have jointly been 
conducting TB surveillance for Europe. Data for the EU 
and  EEA  countries  are  reported  to  the  ECDC  through 
the European surveillance system, TESSy.
Since the reporting year 1998, DST results from initial 
M. tuberculosis isolates have been collected for isoni-
azid,  rifampicin,  ethambutol  and  streptomycin.  Since 
2009, DST data for MDR TB cases on fluoroquinolones 
(ciprofloxacin,  ofloxacin)  and  second-line  injectable 
anti-TB drugs (amikacin, kanamycin and capreomycin) 
have been collected and reports have included retro-
spective data from 2007 and 2008. In this study, data 
was  extracted  from  TESSy  for  EU  and  EEA  countries 
reporting resistance to first-line drugs for the report-
ing year 2008. For the reporting years 2007 and 2008, 
data was extracted for EU and EEA countries reporting 
resistance to second-line drugs for MDR TB cases.5 www.eurosurveillance.org
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The total number of cases, the total number of culture-
positive cases and the total number of cases with DST 
results (sensitive or resistant to at least isoniazid and 
rifampicin) were extracted to assess the interpretabil-
ity of DST data. 
The  proportions  of  drug-resistant  cases  were  calcu-
lated  using  the  total  number  of  cases  with  available 
DST results for at least isoniazid and rifampicin as a 
denominator; if these cases also included results for 
ethambutol  and  streptomycin,  DST  results  for  these 
antibiotics  were  also  analysed.  Cases  of  MDR  TB 
were defined as cases resistant to at least isoniazid 
and  rifampicin.  In  order  to  analyse  findings  on  MDR 
TB  among  new  and  retreatment  cases,  MDR  TB  data 
among reported cases were stratified by history of pre-
vious treatment. New cases were defined as cases who 
had never previously received drug treatment for active 
TB, or who had received anti-TB drugs for less than one 
month. Retreatment cases were defined as cases who 
had received treatment with anti-TB drugs (excluding 
preventive therapy) for at least one month.
Among  MDR  TB  cases  reported  for  2007  and  2008, 
those with positive DST results for any of the report-
able fluoroquinolones as well as to at least one of the 
reportable injectables were classified as XDR TB cases. 
The standard international definition for XDR TB was 
Table 2
Multidrug-resistant cases by previous history of tuberculosis treatment in the EU/EEA, 2008
New  Retreatment Treatment history unknown 
Country 
Cases with DST 
results  
Multidrug-resistant Cases with DST 
results  
Multidrug-resistant Cases with DST 
results  
Multidrug-
resistant
N (%) N (%) N (%)
Austria - - - - - - - - -
Belgium1 621 14 (2.3) 57 7 (12.3) 95 1 (1.1)
Bulgaria 833 14 (1.7) 105 18 (17.1) 0 0 -
Cyprus 11 0 (0.0) 3 1 (33.3) 22 0 (0.0)
Czech Republic 483 10 (2.1) 37 1 (2.7) 0 0 -
Denmark1 253 0 (0.0) 28 0 (0.0) 0 0 -
Estonia 272 42 (15.4) 75 32 (42.7) 0 0 -
Finland 238 1 (0.4) 9 0 (0.0) 0 0 -
France 1,313 16 (1.2) 104 10 (9.6) 139 1 (0.7)
Germany 2,450 16 (0.7) 153 21 (13.7) 343 8 (2.3)
Greece - - - - - - - - -
Hungary 509 8 (1.6) 97 6 (6.2) 5 2 (40.0)
Iceland 4 1 (25.0) 0 0 (0.0) 1 0 (0.0)
Ireland1 113 2 (1.8) 9 0 (0.0) 24 1 (4.2)
Italy 1,018 27 (2.7) 165 24 (14.5) 749 20 (2.7)
Latvia 684 83 (12.1) 144 46 (31.9) 0 0 -
Liechtenstein - - - - - - - - -
Lithuania 1,259 113 (9.0) 356 162 (45.5) 1 1 (100.0)
Luxembourg - - - - - - - - -
Malta 22 0 (0.0) 3 0 (0.0) 0 0 -
Netherlands 696 11 (1.6) 23 2 (8.7) 9 0 (0.0)
Norway1 174 1 (0.6) 20 2 (10.0) 33 1 (3.0)
Poland - - - - - - - - -
Portugal 1,496 19 (1.3) 145 9 (6.2) 0 0 -
Romania 3,025 130 (4.3) 2,522 686 (27.2) 0 0 -
Slovakia 300 1 (0.3) 61 2 (3.3) 22 1 (4.5)
Slovenia 183 1 (0.5) 12 1 (8.3) 0 0 -
Spain 1,080 31 (2.9) 174 23 (13.2) 374 22 (5.9)
Sweden 341 7 (2.1) 38 4 (10.5) 44 1 (2.3)
United Kingdom1 3,707 38 (1.0) 228 7 (3.1) 873 8 (0.9)
Total EU/EEA 21,085 586 (2.8) 4,568 1,064 (23.3) 2,734 67 (2.5)
DST: drug sensitivity testing; EEA: European Economic Area; EU: European Union; TB: tuberculosis.
- : not reported
1  Any resistance to isoniazid, rifampicin, ethambutol or streptomycin, expressed as a percentage of cases with available DST results at least 
to isoniasid and rifampicin. Testing for ethambutol and streptomycin not routine in all countries.7 www.eurosurveillance.org
therefore  applied  [14].  Changes  in  the  prevalence  of 
XDR TB among MDR TB cases between 2007 and 2008 
were analysed.
Findings
In  2008,  47,742  culture-positive  TB  cases  were 
reported by 27 EU and EEA Member States. This rep-
resents 57.8% of the total TB case load (82,611), with 
the  percentage  ranging  from  36.2%  to  100%  among 
the reporting countries (Table 1). Data on resistance to 
first-line drugs in 2008 were available for 25 countries, 
representing a total of 28,295 cases (66.3% of the total 
culture-positive  cases,  excluding  culture-confirmed 
cases  from  Poland  as  DST  data  was  not  reported) 
(Table 1). 
In  2008,  the  proportion  of  culture-positive  TB  cases 
resistant  to  any  first-line  anti-TB  drug  was  15.3% 
(N=4,343). The proportion of resistance to either iso-
niazid or rifampicin among culture-positive cases was 
12.4%  (N=3,513)  and  6.6%  (N=1,876),  respectively 
(Table 1). The proportion of combined (new and retreat-
ment) MDR TB cases in the 25 countries was 6.0%, as 
shown in Table 1. The Baltic States (Latvia, Lithuania 
and Estonia) and Romania showed the highest propor-
tions  (15.6%,  17.1%  21.3%  and  14.7%,  respectively) 
of MDR TB cases (Table 1). The overall proportion of 
MDR  TB  among  new  cases  was  2.8%,  ranging  from 
0% to 25%, and was again highest in the Baltic States 
(9.0%–15.4%) and Iceland (25.0%, one case). Among 
retreatment cases, the overall proportion of MDR cases 
was 23.2%, with the highest proportions in the Baltic 
States  (31.9%-45.5%),  Cyprus  (33.3%,  one  case)  and 
Romania (27.2%) (Table 2).
Thirteen countries provided data on resistance to sec-
ond-line drugs, allowing the identification of XDR TB 
cases for the reporting years 2007 and 2008. Among 
the  total  of  1,122  MDR  TB  cases  (new  and  retreat-
ment  cases)  reported  by  these  13  countries  in  2007, 
68 were XDR TB cases, representing 6.1% of the total 
MDR TB burden. In 2008, 90 XDR TB cases were noti-
fied, with the proportion of XDR TB cases among MDR 
TB cases increasing to 7.3%. Latvia and Romania had 
the highest number of XDR TB cases in 2008 (19 and 54 
cases, respectively). In Estonia, a decline in the total 
number  and  proportion  of  XDR  TB  cases  from  12  to 
nine cases (15.0% to 12.2%) was observed compared 
to 2007, while in Latvia had an increase in the number 
of reported XDR TB cases in 2008 relative to 2007 from 
six to 19 cases (6.1% to 14.7%) (Table 3). 
Conclusions
The  data  highlight  two  important  findings  concern-
ing the MDR/XDR TB situation in the EU/EEA Member 
States. First, it is evident that reporting completeness 
remains  suboptimal  in  this  region.  In  particular,  the 
percentage of the total TB case load for which the drug 
resistance profile for at least isoniazid and rifampicin is 
known, remains low. The DST results were available for 
only 34.4% of the total notified cases (28,295 of 82,611 
cases in 2008), reflecting a low culture positivity rate 
(57.5%)  and  a  low  DST  coverage  (66.4%  of  culture-
positive cases). This represents not only a surveillance 
limitation, but it could also hamper the implementation 
of proper TB control practices such as infection control 
and case management.
Secondly,  the  data  highlights  the  fact  that  MDR  TB 
persists as a threat to the EU/EEA. This is underlined 
by four of the five WHO High Priority Countries within 
the  EU/EEA  (Estonia,  Latvia,  Lithuania  and  Romania) 
reporting proportions of combined MDR TB of well over 
10% of the total case load [15]. The analysis of MDR 
Table 3
Extensively drug-resistant tuberculosis cases in the EU/EEA, 2007-2008
Total MDR-TB Total XDR-TB
XDR/MDR 
%
Total MDR-TB Total XDR-TB
XDR/MDR 
%
Belgium 14 1 (7.1) 22 2 (9.1)
Bulgaria 76 0 (0.0) 32 0 (0.0)
Cyprus 3 0 (0.0) 1 0 (0.0)
Czech Republic 8 0 (0.0) 11 1 (9.1)
Estonia 80 12 (15.0) 74 9 (12.2)
Iceland 1 0 (0.0) 1 0 (0.0)
Latvia 99 6 (6.1) 129 19 (14.7)
Norway 3 1 (33.3) 4 0 (0.0)
Romania 701 47 (6.7) 816 54 (6.6)
Slovakia 7 0 (0.0) 4 0 (0.0)
Spain 59 0 - 76 3 (3.9)
Sweden 15 1 (6.7) 12 1 (8.3)
United Kingdom 56 0 (0.0) 53 1 (1.9)
Total EU/EEA 1,122 68 (6.1) 1,235 90 (7.3)
MDR: multidrug-resistant; EEA: European Economic Area; EU: European Union; TB: tuberculosis; XDR: extensively drug-resistant.8 www.eurosurveillance.org
TB  reporting  can  be  used  to  indicate  weaknesses  in 
TB control programmes. The high proportion of MDR 
TB among new TB cases reported by certain countries 
could suggest suboptimal infection control, whilst the 
high percentage of MDR TB among retreatment cases 
(23.3%) could suggest poor case holding and follow-
up or suboptimal use of TB regimens during the past 
decade. 
For  the  first  time  since  the  surveillance  of  anti-TB 
drugs  has  been  performed  at  EU  level,  notification 
data on XDR TB is available through the joint surveil-
lance system. Although the quality and completeness 
of  second-line  resistance  data  remains  questionable, 
the numbers confirm that XDR TB is now established in 
the EU. The increase of 32.4% in reported XDR TB cases 
is difficult to interpret as this could well represent an 
improvement in DST coverage for second-line drugs, as 
opposed to representing a true increase in the preva-
lence of XDR TB. 
The link and interdependence between TB surveillance, 
TB case management and control of drug-resistant TB 
is  well  reflected  by  these  data.  Improvement  in  the 
quality and completeness of MDR/XDR TB surveillance 
data is needed. This will be achieved by the countries’ 
serious commitment to optimise TB control practices 
as well as improve TB case management, which in turn 
should reverse the of MDR/XDR TB trends observed in 
recent years.
References
1.  Global tuberculosis control: surveillance, planning, financing: 
WHO report 2007. Geneva: World Health Organization; 2007. 
2.  Global tuberculosis control: epidemiology, strategy, 
financing: WHO report 2009. Geneva: World Health 
Organization; 2009. Available from: http://whqlibdoc.who.int/
publications/2009/9789241563802_eng.pdf 
3.  Zignol M, Hosseini MS, Wright A, Weezenbeek CL, Nunn P, Watt 
CJ, et al. Global incidence of multidrug-resistant tuberculosis. J 
Infect Dis. 2006;194(4):479–85. 
4.  Aziz MA, Wright A, Laszlo A, De Muynck A, Portaels F, 
Van Deun A, et al. Epidemiology of antituberculosis drug 
resistance (the global project on anti-tuberculosis drug 
resistance surveillance): an updated analysis. Lancet. 
2006;368(9553):2142–54. 
5.  Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, 
Reniero A, et al. Global trends in resistance to antituberculosis 
drugs. World Health Organization–International Union 
against Tuberculosis and Lung Disease Working Group on 
Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med. 
2001;344(17):1294–303. 
6.  WHO launches new Stop TB strategy to fight the global 
tuberculosis epidemic. Indian J Med Sci. 2006;60(3):125–6. 
7.  Anti-tuberculosis drug resistance in the worl: Fourth global 
report. The WHO/IUATLD Global Project on Anti-Tuberculosis 
Drug Resistance Surveillance 2002-2007. Geneva: World Health 
Organization; 2008. Available from; http://www.who.int/tb/
publications/2008/drs_report4_26feb08.pdf 
8.  Guidelines for the programmatic management of drug-resistant 
tuberculosis. Emergency Update 2008. Geneva: World Health 
Organization; 2008. Available from: http://whqlibdoc.who.int/
publications/2008/9789241547581_eng.pdf 
9.  Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo 
U, et al. Extensively drug-resistant tuberculosis as a cause of 
death in patients co-infected with tuberculosis and HIV in a 
rural area of South Africa. Lancet. 2006;368(9547):1575–80. 
10.  Shah NS, Wright A, Bai GH, Barrera L, Boulahbal F, Martín-
Casabona N, et al. Worldwide emergence of extensively drug-
resistant tuberculosis. Emerg Infect Dis. 2007;13(3):380–7. 
11.  Manissero D, Fernandez de la Hoz K. Extensive drug-resistant 
TB: a threat for Europe? Euro Surveill. 2006;11(39). pii=3056. 
Available from: http://www.eurosurveillance.org/ViewArticle.
aspx?ArticleId=3056 
12.  Hollo V, Amato-Gauci A, Ködmön C, Manissero D. Tuberculosis 
in the EU and EEA/EFTA countries - what is the latest data 
telling us?. Euro Surveill. 2009;14(11). pii=19151. Available 
from: http://www.eurosurveillance.org/ViewArticle.
aspx?ArticleId=19151 
13.  Schwoebel V, Lambregts van Weezenbeeck CS, Moro 
ML, Drobniewski F, Hoffner SE, Raviglione MC, et al. 
Standardisation of antituberculosis drug resistance 
surveillance in Europe. Recommendations of a World 
Health Organization (WHO) and International Union against 
Tuberculosis and Lung Disease (IUATLD) Working Group. Eur 
Respir J. 2000;16(2):364–71. 
14. Extensively drug-resistant tuberculosis (XDR TB): 
recommendations for prevention and control. Wkly Epidemiol 
Rec. 2006;81(45):430-32. 
15.  Plan to Stop TB in 18 High-priority Countries in the WHO 
European Region, 2007–2015. Copenhagen: World Health 
Organization Regional Office for Europe; 2007. Available from: 
http://www.euro.who.int/document/E91049.pdf9 www.eurosurveillance.org
Rapid communications
A possible foodborne outbreak of hepatitis A in the 
Netherlands, January-February 2010
M Petrignani (m.petrignani@ggdzhw.nl)1, L Verhoef2, R van Hunen1, C Swaan3, J van Steenbergen3, I Boxman4, H J Ober5, H 
Vennema2, M Koopmans2
1.  Department of Infectious Disease Control, Public Health Service, Zoetermeer, the Netherlands
2. Laboratory for Infectious Diseases and Screening, Centre for Infectious Disease Control, National Institute for Public Health  
  and the Environment (Rijksinstituut voor Volksgezondheid en Milieu , RIVM), Bilthoven, the Netherlands
3. Preparedness and Response Unit, Centre for Infectious Disease Control, National Institute for Public Health and the  
  Environment (Rijksinstituut voor Volksgezondheid en Milieu , RIVM), Bilthoven, the Netherlands
4. Food and Consumer Product Safety Authority, Zutphen, The Netherlands
5.  Food and Consumer Product Safety Authority, Amsterdam, the Netherlands
Citation style for this article: 
Citation style for this article: Petrignani M, Verhoef L, van Hunen R, Swaan C, van Steenbergen J, Boxman I, Ober HJ, Vennema H, Koopmans M. A possible foodborne 
outbreak of hepatitis A in the Netherlands, January-February 2010. Euro Surveill. 2010;15(11):pii=19512. Available online: http://www.eurosurveillance.org/
ViewArticle.aspx?ArticleId=19512
This article has been published on 18 March 2010
As of 1 March 2010, a total of 11 primary cases with 
onset  of  symptoms  between  31  December  2009  and 
10 February 2010, have been identified with identical 
hepatitis  A  genotype  IB  strains  in  the  Netherlands. 
A relation with Australian and French foodborne out-
breaks occurring in 2009 and 2010 is suspected. Ten 
of the 11 primary cases indicated that they had con-
sumed  one  or  more  products  containing  semi-dried 
tomatoes during their incubation period.
On 12 February 2010, the virology reference laboratory 
for hepatitis A sequencing in the Netherlands detected 
a  new  hepatitis  A  virus  (HAV)  strain  in  five  patients 
with acute hepatitis. The patients did not reveal com-
mon  exposures  and  they  were  geographically  dis-
persed. Their onset of disease ranged between 11 and 
22  January  2010.  Although  the  number  of  reported 
cases was normal for the time of the year, finding five 
identical HAV genotype IB strains was unusual and led 
to an outbreak investigation that is still ongoing in the 
Netherlands. Here we describe the preliminary results 
of this ongoing investigation. 
Epidemiological investigation
The cases included in the cluster were defined as all 
reported hepatitis A infections in the Netherlands with 
date of onset of disease from 15 December 2009 until 
present, with viruses with an identical sequence in a 
fragment of the VP1-2A region [1,2].
The  cases  included  for  a  case  control  study  were 
defined  as  all  reported  hepatitis  A  infections  in  the 
Netherlands  with  date  of  onset  of  disease  from  15 
December 2009 until present. Exclusion criteria were: 
•	   most  probable  source  of  infection  outside  the 
Netherlands  or  outside  any  western  European 
country, 
•	   most  probable  route  of  transmission  sexual  con-
tact between men,  
•	   detection of a non-related HAV strain, 
•	   secondary cases. 
The absolute number of reported cases in the period 
under investigation, January and February 2010, was 39 
and the proportion of cases that contracted their infec-
tion in the Netherlands was 82%. This number is not 
elevated compared with previous years. Between 2005 
and 2009, the number of HAV reports in the Netherlands 
in January and February had ranged between 23 and 
44, with a median of 33. The proportion of cases that 
contracted their infection in the Netherlands in these 
months ranged between 66% and 80%, with a median 
of 68%, and mostly reflects onward transmissions fol-
lowing  the  wave  of  travel-associated  primary  cases 
that is usually seen in autumn [3,4]. 
Of the 39 cases notified in January and February 2010 
(Figure 1), 24 had no history of recent travel abroad, 
denied sexual contact between men and had no known 
relation to another patient or cluster. 
Serum samples from 31 of the 39 notified persons were 
available for PCR. Of these, 21 yielded a PCR product 
that could be used for sequencing. The genotypes iden-
tified were IA (three patients), IIIA (two patients) and IB 
(16 patients). Of the 16 IB sequences, 13 were identical 
with closest genetic relatedness to viruses identified 
in travellers returning from Turkey, and three were dis-
tinct and clustered with strains commonly identified in 
travellers from Morocco.  The 13 patients with identical 
strains were contacted for further investigation.
 
As of 1 March 2010, a total of 11 primary cases, six male 
and five female aged between 20 and 63 years, with 
onset of symptoms between 31 December 2009 and 10 
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genotype 1B strains. Ten of the 11 primary cases indi-
cated that they had consumed one or more products 
containing semi-dried tomatoes during their incubation 
period. The 11th case could not be reached. Two addi-
tional cases infected with the same strain are consid-
ered to be secondary cases (Figure 1). Both were closely 
related to a primary case and their onset of symptoms 
was approximately two weeks after the onset date of 
the suspected index case. 
Two male patients in their late 30s and 50s developed 
liver failure, for which they needed a liver transplan-
tation. They did not have underlying liver disease. We 
are unable to explain the severe outcome of these two 
patients. Usually, the rate of fulminant liver disease is 
less than 1,5% of hospitalised hepatitis A patients [5].
Related outbreaks
The HAV strain was found to be identical to an HAV IB 
strain involved in food-related hepatitis A outbreaks in 
Australia during 2009, based on a 300 nt overlapping 
sequence of the VP1-2A part of the genome (kindly pro-
vided by MJ Lyon, Public Health Virology Laboratory, 
Queensland,  Australia)  [6,7].  Furthermore,  an  out-
break of hepatitis A had occurred in France between 
November  2009  and  January  2010  (personal  commu-
nication). The strain identified in the French outbreak 
(kindly provided by AM Roque-Afonso, Laboratoire de 
Virologie, Hôpital Paul Brousse, Villejuif, France) also 
belonged to the IB genotype, but differed in 2 nt from 
the  Australian  strain  (based  on  a  300  nt  fragment), 
and in 3 nt from the Dutch strain (based on a 430 nt 
fragment).
Although this is a small difference, it should be consid-
ered significant, as typically a single unique strain is 
observed in outbreaks of HAV. Having said that, both 
strains cluster with viruses known to circulate in the 
same  geographic  region  that  includes  Turkey.  This 
is concluded on the basis of sequence data obtained 
from HAV-infected returning travellers. It does not pro-
vide robust evidence for a source of infection, because 
the level of sampling in populations in the wider region 
is insufficient. 
Source tracing
Since  no  other  epidemiological  connection  between 
the cases could be made, a common food source was 
considered most likely. A case control study was initi-
ated to assist in identifying the food product involved, 
and results are not yet available.
In  case  control  studies  in  Australia  and  France,  the 
recent occurrence of HAV infection was associated with 
consumption  of  semi-dried  tomatoes.  Therefore,  the 
Dutch  Food  and  Consumer  Product  Safety  Authority 
started an investigation focusing on products contain-
ing this ingredient eaten by the primary cases in the 
current outbreak. These differed in the way they were 
presented  for  purchase  and  were  purchased  in  dif-
ferent supermarkets, markets or delicacy stores. Full 
trace  back  to  the  area  of  production  is  ongoing.  So 
far, ten different product types of semi-dried tomatoes 
have been identified as consumed by the Dutch cases, 
imported  from  three  different  countries.  No  original 
samples are available for investigation, but as yet, 52 
food  samples  of  similar  products  have  been  tested, 
in which HAV RNA could not be detected. No common 
producer or distributor could be identified so far that 
would explain all the Dutch cases. 
The same applies for a link between the outbreaks in 
the Netherlands, Australia and France. France was able 
to trace the batch of semi-dried tomatoes implicated 
in  the  French  outbreak,  but  no  leftovers  of  this  spe-
cific batch were found. Because the French and Dutch/
Australian  HAV  strains  were  not  identical,  the  exact 
Figure 
Cases  of hepatitis A notified in the Netherlands in January and February 2010 (n=39)
Notified cases include all notifications in this period. Primary and secondary cases include those cases with an identical strain related to the 
possible food-borne cluster, identified as of 1 March 2010.
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sources and modes of transmission of the outbreak in 
the Netherlands remain to be established. 
Conclusions
We have identified a cluster of patients infected with an 
identical HAV IB strain. As the partial strain sequence 
showed a 100% match with viruses found as the cause 
of  foodborne  outbreaks  in  Australia,  and  high  simi-
larity with the HAV strain causing a recent foodborne 
outbreak in France, a possible common source to these 
outbreaks is currently being investigated. Trace back 
investigations so far showed a highly complex market 
for one of the products considered as a possible source 
(semi-dried tomatoes), and failed to identify a common 
link between all cases. This is similar to observations 
in Australia where after an initial small outbreak, a sec-
ond wave was observed that involved a large increase 
in locally-acquired cases compared to previous years 
[6,7 and personal communication]. Therefore, although 
we  have  not  received  reports  of  confirmed  primary 
cases since 17 Feb 2010 (onset of disease 10 Feb 2010), 
this calls for vigilance in the weeks to come. 
We  are  interested  in  all  cases  that  may  be  linked  to 
this  outbreak.  Strains  can  be  compared  using  the 
HAV  database  of  the  Food-borne  Viruses  in  Europe 
(FBVE)  network  at  the  Dutch  National  Institute  for 
Public Health and the Environment (Rijksinstituut voor 
Volksgezondheid en Milieu, RIVM). For details, please 
contact fbve@rivm.nl.
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A cluster of 14 cases of Salmonella Urbana cases in 
Finland,  the  Czech  Republic  and  Latvia  were  identi-
fied in January-February, 2010. The majority of cases 
(11) were male and children under 16 years of age. The 
investigation is currently ongoing and comparison of 
pulsed-field gel electrophoresis (PFGE) profiles of the 
isolates suggests that the cases may have a common 
source of infection.
On 5 February, the Finnish National Salmonella Centre 
(NSC) in the Bacteriology Unit of the Finnish National 
Institute for Health and Welfare (THL) reported four lab-
oratory confirmed cases of S. Urbana (30:b:enx) to the 
THL Unit of Epidemiologic Surveillance and Response. 
Isolates originated from different parts of the country. 
The samples were taken between 13 and 30 January. 
According to the patients’ physicians, none of them had 
been travelling abroad prior to the onset of illness with 
symptoms of diarrhoea and fever. Three of the cases 
were children under four years. A link between the cases 
was suspected because of temporal association of iso-
lates of a very unusual Salmonella serotype. During the 
last 30 years, only three human cases of domestically 
acquired S. Urbana were reported in Finland. According 
to  the  Finnish  Food  Safety  Authority,  S.  Urbana  was 
found once in peanuts (in 2003) and in dog treats (in 
2008). [H. Kuronen; personal communication].
In order to build a hypothesis of the source of the infec-
tion, cases or their guardians were interviewed using 
an  extensive  questionnaire  focussing  especially  on 
food items generally consumed by children and to ani-
mal contacts, or contacts to animal feed. To map the 
occurrence  of  S.  Urbana  infection  in  other  European 
countries,  an  inquiry  to  detect  potentially  linked 
cases  in  other  countries  was  conducted  through  the 
Programme  on  Food-  and  Waterborne  Diseases  and 
Zoonoses network [5].
Table 
Clinical characteristics of S. Urbana cases, Finland, Latvia and the Czech Republic, 2010
Country Age Gender Clinical picture Sample Hospital care
Finland 11 months F bloody diarrhoea faecal yes
Finland 1 year F bloody diarrhoea faecal yes
Finland 13 years F bacteraemia, no gastrointestinal symptoms blood yes
Finland 3,5 years M diarrhoea faecal no
Finland 2 years M bacterial arthritis, no gastrointestinal symptoms faecal+synovial fluid yes
Finland 13 years M diarrhoea faecal no
Finland 35 year M diarrhoea faecal yes
Latvia 2 years M diarrhoea faecal  
Czech Republic 7 years M watery diarrhoea faecal yes
Czech Republic 4 years M diarrhoea faecal no
Czech Republic 6 years M vomiting* faecal yes
Czech Republic 1,3 years M diarrhoea faecal yes
Czech Republic 20 years M bacteraemia, no gastrointestinal symptoms blood yes
Czech Republic 2,5 years M diarrhoea faecal yes
* Vomiting since November 2009, no diarrhoea/abdominal pain, hospitalised 18.1.201013 www.eurosurveillance.org
Investigations to date
A case was defined as a person with S. Urbana (30:b:enx, 
PFGE  profile  SURBXB.0002  and  SURBXB.0003)  infec-
tion in the European Union (EU) with the date of sam-
pling between 1 January and 14 February 2010. In total 
14 cases met the case definition (Table 1). 
Twelve of the cases were children under 16 years. The 
median age was five years (age range 11 months old 
to 35 years old). Eleven were males. Three cases had 
a bacterial invasive disease, Salmonella isolated from 
blood or synovial fluid. Ten cases were hospitalised. 
Seven cases were from different parts of Finland, six 
from  different  parts  of  the  Czech  Republic  and  one 
from Latvia. In Finland, the descriptive epidemiologi-
cal  study  suggested  that  all  cases  could  have  been 
exposed to dogs and all children had eaten raisins. In 
the Czech Republic, the epidemiological investigation 
revealed contact with dogs only in two cases and con-
sumption of raisins in one case. No potential common 
source was detected in the Czech cases. The Latvian 
case had had no contact with dogs and had not con-
sumed raisins, but the family had a cat whose feed was 
sampled and tested with negative results. The dog fae-
ces, dog treats and raisins collected from the homes of 
the Finnish cases tested negative for salmonella. 
PFGE  profiles  from  the  three  countries,  Finland,  the 
Czech  Republic  and  Latvia,  were  indistinguishable 
when compared to each other (Figure 1) indicating that 
the infections might have had a common source. 
One Finnish PFGE profile (SURBXB.0003) had an extra 
band.  This  minor  difference  might  be  caused  by  a 
plasmid which salmonellae can spontaneously lose or 
acquire. It is also possible that a recent point muta-
tion,  deletion  or  insertion  in  the  DNA  had  occurred. 
S.  Urbana  strains  were  sensitive  to  all  antimicrobial 
agents  tested  (ampicillin,  chloramphenicol,  cefotax-
ime,  imipenem,  mecillinam,  nalidixic  acid,  neomycin, 
sulfonamide, tetracycline, trimethoprim, streptomycin, 
and ciprofloxacin).
Conclusions to date
An  unusual  Salmonella  serotype  leading  to  a  high 
rate of hospitalisation and the severe clinical picture 
of  the  cases  detected  in  Finland  and  in  the  Czech 
Republic  were  important  reasons  for  triggering  the 
epidemiological investigation. According to data from 
the  Finnish  Infectious  Disease  Registry  data  base 
gathered between 2000 and 2009, less than 2% of all 
non-typhoidal  salmonella  findings  were  from  blood. 
Similarly, in a large Spanish study, 4.5% of the patients 
with salmonellosis had septicaemia [1]. In the current 
cluster of S. Urbana, three cases of 14 had an invasive 
extraintestinal disease; two with bacteraemia and one 
with hematogeneous septic arthritis. 
S. Urbana is rarely described in the literature. In the 
1990s, a large outbreak occurred in a neonatal ward in 
Thailand [2] and a case of S. Urbana encephalopathy 
was reported from Japan [3]. The inquiry to the experts 
in the Programme on Food- and Waterborne Diseases 
and Zoonoses revealed that S. Urbana is rare in Europe 
in general, and mostly reported in children.  Some of 
these  cases  had  been  associated  with  contacts  with 
reptiles  [4].    S.  Urbana  has  also  been  found  in  ses-
ame  and  equsi  (melon)  seeds,  black  pepper,  animal 
feed and sewage sludge, according to experts in the 
Programme  on  Food-  and  Waterborne  Diseases  and 
Zoonoses network.
 
Only one of the cases (in the Czech Republic) had had 
contact with a reptile. According to our investigations, 
neither animals nor their feed seem to be the source 
of the current infections. Milk products appear to be 
less likely to be the source of infection, since one of 
the cases suffered from severe milk allergy. Fish, nuts, 
soya products and health food items were rarely con-
sumed by the Finnish cases. Most of the cases were 
males,  but  we  were  not  able  to  reveal  any  exposure 
common to the cases that could have been linked to 
being male.
Since the beginning of February, no further cases of 
S. Urbana have been detected in the three countries. 
Most  of  the  cases  had  accumulated  in  two  weeks  in 
January in all three countries. The cases detected in the 
beginning of February were in a cancer patient without 
gastrointestinal symptoms (Salmonella found in blood) 
Figure 2
Cases of S. Urbana by date of onset of gastrointestinal 
symptoms and country, 12 January-7 February 2010
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Figure 1
PFGE profiles of S. Urbana isolates from Finland, Czech 
Republic and Latvia when digested with XbaI enzyme.
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and  an  adult  male  who  was  considered  a  secondary 
case to his children that also suffered from gastroin-
testinal symptoms. When tested, however, the family 
members were negative for Salmonella. The accumula-
tion of most cases with gastrointestinal symptoms in 
two weeks (Figure 2) suggests that the source of the 
infection could have been a product with a short shelf-
life such as a batch of fresh produce, or a minor con-
tamination of some other product. To date however, the 
source of the outbreak remains unknown.
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This paper describes the results of second-line drug 
(SLD)  susceptibility  tests  among  multidrug-resistant 
tuberculosis (MDR TB) cases reported in 20 European 
countries aiming to identify extensively drug-resistant 
tuberculosis  (XDR  TB)  cases.  A  project  on  molecu-
lar  surveillance  of  MDR  TB  cases  was  conducted  by 
EuroTB  and  the  National  Institute  for  Public  Health 
and  the  Environment  (RIVM)  from  2005  to  2007. 
Information on drug susceptibility testing (DST) was 
provided to this project and case-based data on MDR 
TB  cases  were  reported  on  a  quarterly  basis  by  20 
countries of the World Health Organization’s European 
Region, including 15 European Union Member States. 
Data  included  SLD  susceptibility  test  results,  ena-
bling a retrospective description of XDR TB cases noti-
fied between 2003 and 2007. In 18 countries DST was 
performed for two or more of the SLD included in the 
XDR TB definition. The proportion of MDR TB isolates 
tested for SLD varied widely between countries (range 
20 to 100 percent). In the 18 countries, 149 (10%) XDR 
TB  cases  were  reported  among  MDR  TB  cases  with 
available DST results for SLD. Sixteen additional MDR 
TB  cases  were  reported  by  the  MDR  TB  surveillance 
system when compared with the number of routinely 
reported MDR TB cases to EuroTB in ten countries with 
representative data reported during three consecutive 
years (2003-2005). To counter the threat of XDR TB in 
Europe,  a  standardised  approach  to  XDR  TB  surveil-
lance and DST for SLD is needed, as well as increased 
laboratory capacity across European countries.
Introduction
Extensively  drug-resistant  tuberculosis  (XDR  TB)  is 
a  worldwide  threat  to  TB  control,  as  XDR  TB  cases 
are  extremely  difficult  to  treat  [1].  The  origin  of  XDR 
TB  is  linked  to  the  introduction  of  second-line  anti-
tuberculosis drugs (SLD) for the treatment of multid-
rug-resistant  tuberculosis  (MDR  TB)  and  the  possible 
mismanagement of patients (including failure of com-
pliance) under SLD treatment [2,3]. In March 2006, the 
term XDR TB first appeared in the literature in a United 
States Centers for Disease Control and Prevention (US 
CDC)  report  describing  the  findings  of  a  worldwide 
survey on anti-TB drug resistance carried out between 
2000 and 2004 [4]. Since then, a number of scientific 
and  media  reports  on  XDR  TB  have  been  published 
[5]. Although the term has emerged only recently, the 
occurrence  of  TB  cases  resistant  to  most  available 
drugs is not new [6]. The definition of XDR TB, MDR TB 
plus resistance to a fluoroquinolone and at least one of 
three injectable SLD (amycacin, kanamycin, capreomy-
cin) has been revised in 2006 because not all the SLD 
included in the original case definition were used and 
tested worldwide [7-9]. 
Epidemics of drug-resistant TB have been described in 
the WHO European Region since the 1990s [10]. XDR TB 
has been identified as a significant problem in coun-
tries of the former Soviet Union [11] and the potential 
threat of XDR TB for Europe has been assessed by the 
European  Centre  for  Disease  Centre  and  Prevention 
(ECDC)  in  2006  [12].  The  occurrence  of  XDR  TB  out-
breaks in patients co-infected with HIV has re-enforced 
the public health awareness, with a particular focus on 
South Africa [13]. 
In  2005,  the  EuroTB  network  started  a  molecular 
surveillance  project  on  MDR  TB  in  24  countries  of 
the  WHO  European  Region  including  19  European 
Union  (EU)  Member  States,  plus  Croatia,  Israel,  the 
Former Yugoslav Republic of Macedonia, Norway and 
Switzerland)  [14].  The  project  was  coordinated  by 
EuroTB in France and the National Institute for Public 
Health and the Environment (RIVM) in the Netherlands 
until the end of 2007. As resistance to SLD was already 
a matter of concern in 2005, data on drug susceptibil-
ity testing (DST) for SLD were collected in addition to 
DNA fingerprint data [14,15]. The project provided an 
opportunity to implement case reporting of XDR TB by 
applying the revised XDR TB case definition of 2006 16 www.eurosurveillance.org
retrospectively. This article describes notification data 
on resistance to SLD in the EU and some neighbouring 
countries from January 2003 through June 2007.
Methods 
Data collection
The MDR TB project included 24 countries of the WHO 
European Region that were able to or planning to par-
ticipate in case-based reporting of molecular data on 
MDR TB cases at European level in 2005. Case-based 
data  on  all  newly  diagnosed  and  culture  confirmed 
positive  MDR  TB  cases  were  reported  by  national 
surveillance institutions (NSI) to EuroTB on a quarterly 
basis from January 2005 through June 2007. Data for 
2003 and 2004 were reported retrospectively. The data 
were collected anonymously, according to a standard-
ised data file specification reviewed by the members 
of the EuroTB advisory committee [16]. Each case had 
a unique record identifier. Common definitions of vari-
ables were used by the participating countries, includ-
ing demographic and clinical variables and results from 
susceptibility testing for first and second-line anti-TB 
drugs. The country of origin of a case was defined as 
Table 1
Reporting of anti-tuberculosis second line DST on Mycobacterium tuberculosis isolates of MDR TB cases in 20 European 
countries, 2003-20071
Country
MDR TB 
cases 
N
Secondline 
drugs tested 
N
Injectable drugs Fluoroquinolones
Amikacin Kanamycin Capreomycin Ciprofloxacin Ofloxacin
N (%) N (%) N (%) N (%) N (%)
Five second line anti-tuberculosis drugs tested
France2 152 5 148 (97) 147 (97) 135 (89) 145 (95) 149 (98)
Czech Republic1 38 5 25 (66) 22 (58) 25 (66) 25 (66) 25 (66)
Norway1 11 5 11 (100) 11 (100) 11 (100) 5 (45) 11 (100)
Ireland1 8 5 3 (38) 1 (13) 3 (38) 3 (38) 1 (13)
Slovenia4 3 5 3 (100) 1 (33) 1 (33) 3 (100) 1 (33)
Four second line anti-tuberculosis drugs tested
Lithuania3 656 4 89 (14) 173 (26) 101 (15) - - 172 (26)
Estonia2 248 4 245 (99) 245 (99) 244 (98) - - 245 (99)
Israel2 45 4 43 (96) - - 43 (96) 44 (98) 44 (98)
Switzerland1 25 4 24 (96) - - 9 (36) 4 (16) 19 (76)
Denmark3 5 4 5 (100) - - 5 (100) 5 (100) 5 (10)
Three second line anti-tuberculosis drugs tested
Latvia1 712 3 - - 705 (99) 698 (98) - - 689 (97)
Romania3 50 3 19 (38) 44 (88) - - 44 (88) - -
Belgium1 31 3 12 (39) 2 (6) - - - - 12 (39)
Poland4 17 3 6 (35) - - 6 (35) - - 6 (35)
Former Yugoslavian Republic 
of Macedonia1
15 3 8 (53) - - 8 (53) 8 (53) - -
Cyprus1 3 3 1 (33) - - 3 (100) - - 3 (10)
 Two second line anti-tuberculosis drugs tested
The Netherlands2 34 2 33 (97) - - - - 34 (100) - -
Croatia2 5 2 1 (20) - - - - 2 (40) - -
One second line anti-tuberculosis drug tested
Spain3 50 1 - - 2 (4) - - - - - -
Sweden1 21 1 15 (71) - - - - - - - -
Total  2,129   691 (51) 1,353 (69) 1,292 (67) 322 (82) 1382 (71)
DST: drug sensitivity testing; MDR TB: multidrug-resistant tuberculosis.
1  Data reported between 2003 and 2007. 
2  Data reported between 2003 and 2005. 
3  Data reported between 2004 and 2005.  
4  Data reported in 2005 and 2006 in Poland ; 2003 and  2005 in Cyprus; 2003, 2005 and  2006 in Slovenia.17 www.eurosurveillance.org
their country of birth (if available) or their country of 
citizenship.
Reporting of drug susceptibility testing for 
second-line drugs and XDR TB cases
DST results for SLD, resistant or susceptible, were col-
lected  for  the  following  drugs:  amikacin,  kanamycin, 
capreomycin,  ciprofloxacin,  ofloxacin.  The  rationale 
behind the choice of the SLD tested was that they rep-
resented  the  most  commonly  used  aminoglycosides 
(injectables) and fluoroquinolones. If no resistance is 
measured against the tested drugs within each of these 
two classes of drugs, it is unlikely that resistance can 
be found against other drugs from the same classes, 
because  of  cross-resistance.  Data  were  validated  by 
EuroTB, eventually completed by the reporting NSI and 
collated into a European MDR TB case database.
The  revised  2006  XDR  TB  case  definition  was  used 
for  the  analysis  [8].  This  definition  refers  to  XDR  TB 
as  resistance  to  at  least  isoniazid  and  rifampicin 
as  well  as  further  resistance  to  a  fluoroquinolone 
(ofloxacin, ciprofloxacin) and at least one second-line 
injectable  aminoglycocide  (amikacin,  kanamycin  and 
capreomycin). 
The number and distribution of MDR TB isolates tested 
for anti-TB second-line DST as well as the number and 
proportion of XDR TB cases by country were calculated. 
The percentage of SLD tested (SLD testing percentage) 
for a given country was defined as the number of tests 
performed for a specific drug divided by the number of 
MDR TB cases reported in that country. The proportion 
of XDR TB cases was calculated using the number of 
MDR TB cases tested for SLD (included in the XDR TB 
definition) as a denominator.
As reported by EuroTB [17], anti-TB drug resistance sur-
veillance (DRS) was performed on nationwide samples 
of TB cases in all 18 countries participating to the MDR 
TB project [14], except for Italy and Spain (partial cov-
erage)  and  Poland  (no  information  about  representa-
tiveness available). Data from Romania was provided 
from a country-wide DST survey. 
The number of MDR TB cases reported to the project 
was  compared  with  the  number  of  MDR  TB  cases 
reported to Euro-TB using drug resistance susceptibil-
ity data.
Table 2
Distribution of MDR and XDR TB cases by country reported in 18 European countries, 2003-20071
Country (number of TB cases 
reported to EuroTB) 
MDR TB cases reported  to 
MDR TB project 
N
MDR TB  isolates tested for 
2-5 SLD  
N (%)
  XDR TB cases 
N 
XDR among MDR TB  cases 
with SLD  DST 
%
Countries with at least 88% of MDR TB cases tested for two to five SLD 
Latvia (6,107) 712 688 (97) 53 8
Estonia (1,736) 248 245 (99) 58 24
France (16,986) 152 149 (98) 1 1
Romania (60,323) 50 44 (88) 2 5
Israel (1,454) 45 44 (98) 2 5
Netherlands (3,820) 34 33 (97) 1 3
Switzerland (2,303) 25 22 (88) 0 0
Norway (1,221) 11 11 (100) 0 0
Denmark (1,200) 5 5 (100) 0 0
Slovenia (1,049) 3 3 (100) 1 33
Cyprus (102) 3 3 (100) 0 0
Total  1,288 1,247 (97) 118 9%
Countries with less than 88% of MDR TB cases tested for two to five SLD 
Lithuania (5,088) 656 173 (26) 25 14
Czech Republic (4199) 38 25 (66) 5 20
Belgium (4,187) 31 12 (39) 0 0
Poland (17,873) 17 6 (35) 0 0
Macedonia (2,662) 15 8 (53) 0 0
Ireland (1,747) 8 3 (38) 1 33
Croatia (3,931) 5 1 (20) 0 0
Total  770 228 (30) 31 14%
Total  2,058 1,475 (72) 149 10%
DST: drug sensitivity testing; MDR TB: multidrug-resistant tuberculosis, XDR TB: extensively drug-resistant tuberculosis; SLD: second line 
drugs.
1  Data reported for at least one year between 2003 and 2007.18 www.eurosurveillance.org
Results
Individual  data  on  SLD  testing  for  Mycobacterium
tuberculosis  isolates  from  2,129  cases  reported 
between  January  2003  and  July  2007  were  available 
for  20  countries  (population  of  259,467,657)  out  of 
24  European  countries  (population  of  467,007,506), 
including 15 EU countries. Data were not reported by 
Germany, Italy, Finland and the United Kingdom, repre-
senting almost half of the total population covered by 
the surveillance project. 
Sixteen additional MDR TB cases were reported by the 
MDR TB surveillance system when compared with the 
number of routinely reported MDR TB cases to EuroTB 
in ten countries with representative data reported dur-
ing three consecutive years (2003-2005) (i.e. Belgium, 
Denmark, Estonia, Ireland, Israel, Latvia, Netherlands, 
Norway, Slovenia, Switzerland) [17]. 
Number of second-line anti-TB drugs 
tested for susceptibility by country
The number of SLD tested varied from one to five by 
country (Table 1). 
In the five countries where SLD testing was reported for 
all five drugs; France, Czech Republic, Norway, Ireland, 
and Slovenia, the proportion of MDR TB cases tested 
(SLD testing percentages) varied from ≥ 13% in Ireland 
to ≥ 58% in the Czech Republic, and ≥ 89% in France. In 
countries where DST was performed for four SLD, cip-
rofloxacin was not tested in Lithuania and Estonia, and 
kanamycin was not tested in Israel, Switzerland, and 
Denmark. Testing percentages were very high (≥ 96%) 
in Estonia and Israel for all the SLD tested. In contrast, 
testing percentages were low in Lithuania (≤ 26%). 
In the six countries where DST was performed for three 
drugs,  amikacin  was  included  in  testing  practices  in 
all the countries, except in Latvia. DST was performed 
for  two  drugs  (amikacin  and  ciprofloxacin)  in  the 
Netherlands  (testing  percentage  ≥  97%)  and  Croatia 
(testing percentage ≤ 40%). Two countries, Sweden and 
Spain tested for one SDL.
In six countries (Norway, Ireland, Slovenia, Denmark, 
Cyprus  and  Croatia),  the  numbers  of  MDR  TB  cases 
reported was small and therefore the results for those 
countries  do  not  necessarily  reflect  the  testing  prac-
tices in these countries.
XDR TB cases reported by country
The  number  of  XDR  TB  cases  was  calculated  for  the 
18  countries  where  MDR  TB  isolates  were  tested  for 
at least two SLD (Table 2). When considering the pro-
portion of MDR TB cases tested for SLD, two groups of 
countries  could  be  distinguished:  group  1,  countries 
with  a  high  (≥  88%)  percentage  of  SLD  testing  and 
group 2, countries with a low (≤ 88%) percentage of 
SLD testing (Table 2). The ten countries in group 1 rep-
resented 63% (1,288/2,058) of reported MDR TB cases 
and 79% of the identified XDR TB cases.
XDR TB cases were detected in 10 countries, of which 
nine  are  EU  Member  States,  and  seven  belonged  to 
group 1. The overall proportion of XDR TB cases among 
MDR TB cases with DST for SLD was 10%. Ninety-one 
percent (136/149) of the XDR TB cases detected were 
reported in the Baltic States, where the percentage of 
XDR TB among MDR TB patients tested for SLD was 8% 
or higher (Table 2). In Estonia, 24% of MDR TB cases 
with  DST  results  for  SLD  were  XDR.  This  percentage 
is based on a highly representative sample of 99% of 
MDR TB patients tested for SLD. Therefore, this result 
indicates a relatively high prevalence of XDR TB among 
MDR  TB  cases  in  this  country.  In  Latvia,  where  SLD 
results were available for 97% of MDR TB, the propor-
tion of XDR TB was three times lower than in Estonia. 
In Lithuania, the proportion of XDR TB (14%) was based 
on  a  sample  of  173  MDR  TB  cases  with  DST  results. 
These 173 patients represent 26% of all reported MDR 
TB cases, which may not have been selected randomly 
meaning  that  only  the  most  severe  cases  may  have 
been  tested  for  SLD.  In  the  Czech  Republic,  the  per-
centage of XDR TB cases was relatively high (20%), but 
the information for SLD testing was only available for 
25 cases, representing 66% of the Czech MDR TB cases 
reported to our project.
Discussion
This  surveillance-based  project  provides  baseline 
data on XDR TB in a large number of European coun-
tries at the time of the establishment of the XDR TB 
case definition. Although four western European coun-
tries with a large population were not included in this 
project,  results  show  that  at  least  one  XDR  TB  case 
was reported in 10 out of 18 European countries. The 
overall proportion of XDR TB among 1,475 (72%) MDR 
TB  patients  tested  for  SLD  was  approximately  10%. 
Ninety-one percent of the reported 149 XDR TB cases 
were  notified  by  the  three  Baltic  countries  (Estonia: 
248  cases,  Latvia:  712  cases,  Lithuania:  656  cases), 
which belonged to the former Soviet Union until 2004. 
This confirms the finding of a worldwide survey con-
ducted by WHO and the US CDC, showing that the pro-
portion of XDR TB among TB patients originating from 
former Soviet Union countries is high. [18]. 
These data have to be interpreted in a broader scope of 
the establishment of TB surveillance and control in the 
WHO European Region [19,20]. The number of XDR TB 
cases detected can partly be affected by differences in 
surveillance systems between countries for case defi-
nitions, the possibility of linking laboratory and noti-
fication data, and by data quality (completeness and 
validity). The revision of the XDR TB definition had an 
impact on the determination of the number of XDR TB 
cases in European countries [8]. According to the previ-
ous case definition, the proportion of XDR among MDR 
TB cases was estimated to be higher in 17 countries 
[12].
The  fact  that  20  out  of  24  participating  countries 
reported SLD test results for at least one drug, and that 19 www.eurosurveillance.org
DST for SLD was performed but not available for report-
ing in at least one other country, the United Kingdom, is 
a positive indicator for the availability of DST for SLD at 
European level. However, the number of XDR TB cases 
reported could be underestimated because of the lim-
ited number of SLD susceptibility testing in some coun-
tries or over-estimated due to lack of standardisation. 
The number and type of SLD tested varied considerably 
between countries. A lack of standardisation and homo-
geneity in drug susceptibility testing practices for SLD 
has been identified by a panel of laboratory experts 
[21]. However, susceptibility testing of SLD has yielded 
reliable and reproducible results for some of the SLD 
[22]. Cross-resistance is common among aminoglyco-
sides and absolute among fluoroquinolones, however, 
not  all  isolates  exhibit  the  same  resistance  profile. 
Despite issues related to cross-resistance, it remains 
important to test a broad panel of SLD [23].  At the time 
of reporting, SLD DST methods had not been standard-
ised or recommended, and External Quality Assurance 
(EQA) was not available, but since 2007 EQA for SLD 
has begun and since 2008 policy guidance has been 
published, which should help in standardising testing 
practices [21]. Therefore, it is expected that SLD DST 
practices  and  standardisation  of  these  will  improve 
significantly within the coming years.
The findings of this project and previous ones [14,18] 
concerning the relatively high rate of 10% XDR among 
MDR TB cases, should have an impact on clinical man-
agement of individual patients and TB control, espe-
cially in eastern European countries. There is a need 
for  new  drugs  and  treatment  strategies.  However, 
while new drugs will only be available in a number of 
years, the utility of derivates of current drugs and also 
alternative drugs like meropenem should be explored 
[24].  Serious  consequences  for  TB  control  may  be 
related to increased travel and migration, as this can 
lead to imported cases MDR TB from eastern Europe to 
western Europe, and transmissible forms of MDR and 
XDR TB are a fearsome scenario [14]. If transmission of 
XDR  TB  is  diagnosed  in  western  European  countries, 
new  strategies  on  monitoring  risks  associated  with 
immigration from and travel to high-incidence settings 
should be developed.
Our  surveillance  project  has  some  limitations  that 
should be taken into account in future MDR and XDR 
TB surveillance in Europe. It would be of considerable 
value if data from the four missing countries could be 
added. In countries with a low proportion of patients 
tested for SLD, (Lithuania, Czech Republic), additional 
data is needed to better interpret the XDR TB preva-
lence. In countries with low numbers of XDR TB cases 
reported (e.g. Ireland and Slovenia), XDR TB percent-
ages can be biased and therefore should not be com-
pared to other countries. 
Conclusion
Further  research  are  conducted  on  the  occurrence  of 
transmitted  MDR  and  XDR  TB  strains  to  investigate 
whether they pose a new evolutionary development of 
M. tuberculosis, or an extend of the current problem. 
Both scenarios would highlight consequences of a long 
lasting,  uncontrolled  problem  and  demonstrate  the 
need for enhanced efforts in TB control in the regions 
where this problem develops. The capacity for SLD test-
ing should be upgraded, especially in areas with high 
numbers of drug-resistant TB cases, such as in eastern 
Europe. As identified in a previous survey [25], stand-
ardisation and quality assurance of laboratory meth-
ods for DST of SLD should be improved across Europe. 
An  EU  reference  laboratory  network  has  been  estab-
lished with EU Member States to support their activi-
ties [26]. Surveillance data on MDR and XDR TB with 
improved quality are essential to determine the mag-
nitude of this threat to TB control. In addition, surveil-
lance data is needed to monitor TB control activities, 
and as a basis for implementing appropriate treatment 
and care and to prioritise laboratory resources.
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An  analysis  of  surveillance  data  was  performed  to 
assess  treatment  outcomes  of  patients  belonging  to 
selected calendar year cohorts. Twenty-two countries 
in  the  European  Union  (EU)  and  European  Economic 
Area  (EEA)  reported  treatment  outcome  monitoring 
data  for  culture-confirmed  pulmonary  tuberculosis 
(TB)  cases  reported  in  2007.  The  overall  treatment 
success rate was 73.8% for all culture-confirmed pul-
monary  cases  and  79.5%  for  new  culture-confirmed 
pulmonary cases. For the cohort of new culture-con-
firmed  TB  cases,  only  three  countries  achieved  the 
target  of  85%  success  rate.  This  underachievement 
appears to be a result of relative high defaulting and 
unknown outcome information. Case fatality remains 
high particularly among cases of national origin. This 
factor  appears  attributable  to  advanced  age  of  the 
national  cohort.  Treatment  outcomes  for  multidrug-
resistant tuberculosis were reported by 15 countries, 
with a range of 19.8% to 100% treatment success at 
24  months.  The  data  underline  the  urgent  need  for 
strengthening  treatment  outcome  monitoring  in  the 
EU and EEA in order to ensure an effective programme 
implementation and case management that will ulti-
mately contribute to TB elimination.
Background 
Tuberculosis  (TB)  remains  a  global  emergency  with 
estimates of 1.8 millions deaths worldwide in 2008 and 
over nine million cases. In 2008, the estimated global 
incidence  rate  fell  to  139  cases  per  100,000  popula-
tion after reaching its peak in 2004 at 143 per 100,000. 
However, this decline was not homogeneous through-
out the World Health Organization (WHO) regions, with 
Europe failing to record a substantial decline, but rather 
appearing to have reached a stabilisation of rates [1].
The 30 Member States of the European Union (EU) and 
European Economic Area (EEA) present a peculiar and 
highly heterogeneous situation in terms of TB epidemi-
ology and control. Three broad epidemiological areas 
are  distinguished  within  the  borders  of  the  EU/EEA: 
low incidence countries (below 20 notified cases per 
100,000 population) with cases aggregating in vulner-
able populations and only occasional increased noti-
fication  rates;  countries  with  moderate-to-high,  but 
declining notification rates and with a low proportion 
of multidrug-resistant (MDR) TB; and finally, countries 
with  relatively  high  notification  rates  (over  100  noti-
fied cases per 100,000) and high levels of MDR TB, but 
again with declining overall TB rates [2-4].
Attention  to  TB  control  in  the  EU  and  EEA  has  been 
raised in recent years through a number of initiatives, 
including the launching of a Framework Action Plan to 
Fight Tuberculosis in the EU [5]. Among the key issues 
underlined in the Action Plan is the need to achieve and 
sustain acceptable levels of treatment success among 
all TB patients.
Treatment success measured by a standardised proc-
ess of treatment outcome monitoring (TOM) is one of 
the  pillars  of  TB  control  and,  along  with  case  detec-
tion,  is  recognised  as  a  key  programmatic  output.  It 
is against this rationale that a World Health Assembly 
(WHA)  resolution  was  passed  in  1991,  adopting  two 
targets for global TB control: to detect at least 70% of 
new infectious cases and to cure at least 85% of those 
detected. These targets were linked to the Millennium 
Development Goals, and the Stop TB Partnership set 
the year 2005 as the deadline for achievement [6-8].
Globally, the treatment success rate has exceeded the 
85% target for the first time in 2008 since the target 
was set in 1991, with a percentage of 87% for patients 
starting  treatment  in  2007.  Furthermore,  treatment 
success  rates  were  maintained  or  improved  between 
2006 and 2007 in all WHO regions with the exception 
of the European Region which recorded the lowest suc-
cess rate globally at 67% [1].
The  importance  of  strengthening  treatment  out-
come  monitoring  in  Europe  has  long  been  recog-
nised.  A  statement  put  forward  by  the  WHO  and  the 
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Disease underlined in 1998 the need for standardisa-
tion and evaluation of treatment results for TB patients 
in  the  WHO  European  region,  including  those  in  low 
and intermediate incidence countries [9].
In this study we aimed to analyse treatment outcomes 
and  progress  towards  the  targets  specifically  for 
the EU/EEA region as a whole and its Member States 
separately. 
Since 1 January 2008, the European Centre for Disease 
Prevention and Control (ECDC) and the WHO Regional 
Office for Europe have jointly coordinated the TB sur-
veillance  in  Europe.  Designated  national  surveillance 
institutions or individuals are responsible for provid-
ing the data, which is reported to a central joint data-
base. Furthermore, historical data are available from 
the former EuroTB project for TB surveillance activities 
in Europe from 1996 to 2007. These data represent a 
valuable source for an in-depth analysis of treatment 
outcome monitoring and were used in our study.
Methods
A  descriptive  analysis  of  surveillance  data  was  per-
formed  to  assess  treatment  outcomes  of  patients 
belonging to selected calendar year treatment cohorts. 
Data  were  extracted  from  The  European  Surveillance 
System  (TESSy)  and  from  the  former  EuroTB  histori-
cal database for the 30 EU and EEA countries report-
ing data to the ECDC. Since the reporting year 2002, 
outcome data are collected for all individual cases by 
submission of an individual dataset for the 12 months 
before the year for which notification data are reported 
to TESSy, and since 2008 also for MDR treatment out-
come  for  cases  reported  24  months  before  the  year 
for which notification data are reported to TESSy. The 
cases eligible for outcome analysis (cohorts) include all 
the culture-confirmed pulmonary TB cases notified in 
the calendar year of interest, after exclusion of cases 
with final diagnosis other than TB.
Country-specific data were extracted for 2007 for both 
new  and  retreatment  laboratory-confirmed  pulmo-
nary TB cases for the analysis of 12 months of treat-
ment  outcome  data.  For  2006,  country-specific  data 
were extracted for laboratory-confirmed MDR TB cases 
(combined new and retreatment) for the analysis of 24 
months  of  treatment  outcome  data.  Aggregated  EU/
EEA data were extracted for the period 2003 to 2007 for 
trend analysis of treatment outcome for new, retreat-
ment  and  combined  laboratory-confirmed  pulmonary 
Figure 1
Treatment outcome of laboratory-confirmed pulmonary cases, EU/EEA countries1 2003-2007
0
10
20
30
40
50
60
70
80
90
100
2003 2004 2005 2006 2007 2003 2004 2005 2006 2007 2003 2004 2005 2006 2007
Year
P
r
o
p
o
r
t
i
o
n
 
o
f
 
c
a
s
e
s
 
(
%
)
Transferred or unknown
Still on treatment
Defaulted
Failed
Died
Success
Previously untreated Previously treated All Pulmonary cases
EEA: European Economic Area; EU: European Union.
1   Excluding countries that did not or not in all years report cases: Austria, Bulgaria, Finland, France, Greece, Liechtenstein, Luxembourg, and 
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Table 1
Treatment outcome in new and retreatment culture-confirmed pulmonary tuberculosis cases, by country, EU/EEA 
countries, 2007 (n=36,377)
Cases notified 
in 2007
Success Died Failed Defaulted
Still on treat-
ment
Transferred or 
unknown
Country N N (%) N (%) N (%) N (%) N (%) N (%)
New cases  
Austria - - - - - - - - - - - - -
Belgium1 499 342 (68.5) 42 (8.4) 0 (0.0) 44 (8.8) 12 (2.4) 59 (11.8)
Bulgaria 1,233 972 (78.8) 85 (6.9) 4 (0.3) 96 (7.8) 41 (3.3) 35 (2.8)
Cyprus - - - - - - - - - - - - -
Czech Republic 459 331 (72.1) 86 (18.7) 4 (0.9) 32 (7.0) 4 (0.9) 2 (0.4)
Denmark1 213 169 (79.3) 11 (5.2) 2 (0.9) 3 (1.4) 11 (5.2) 17 (8.0)
Estonia 302 185 (61.3) 41 (13.6) 2 (0.7) 29 (9.6) 45 (14.9) 0 (0.0)
Finland 181 126 (69.6) 35 (19.3) 1 (0.6) 2 (1.1) 7 (3.9) 10 (5.5)
France - - - - - - - - - - - - -
Germany 2,421 1,863 (77.0) 277 (11.4) 3 (0.1) 36 (1.5) 69 (2.9) 173 (7.1)
Greece - - - - - - - - - - - - -
Hungary 612 311 (50.8) 74 (12.1) 86 (14.1) 34 (5.6) 84 (13.7) 23 (3.8)
Iceland 7 6 (85.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (14.3)
Ireland1 181 127 (70.2) 10 (5.5) 0 (0.0) 3 (1.7) 8 (4.4) 33 (18.2)
Italy - - - - - - - - - - - - -
Latvia 772 634 (82.1) 54 (7.0) 1 (0.1) 32 (4.1) 51 (6.6) 0 (0.0)
Liechtenstein - - - - - - - - - - - - -
Lithuania 1,209 860 (71.1) 144 (11.9) 18 (1.5) 89 (7.4) 94 (7.8) 4 (0.3)
Luxembourg - - - - - - - - - - - - -
Malta 12 9 (75.0) 0 (0.0) 0 (0.0) 1 (8.3) 1 (8.3) 1 (8.3)
Netherlands1 397 314 (79.1) 18 (4.5) 0 (0.0) 8 (2.0) 0 (0.0) 57 (14.4)
Norway1 114 89 (78.1) 2 (1.8) 0 (0.0) 0 (0.0) 4 (3.5) 19 (16.7)
Poland 4,502 3,444 (76.5) 269 (6.0) 12 (0.3) 448 (10.0) 16 (0.4) 313 (7.0)
Portugal 1,694 1,467 (86.6) 90 (5.3) 5 (0.3) 52 (3.1) 56 (3.3) 24 (1.4)
Romania 11,245 9,508 (84.6) 453 (4.0) 442 (3.9) 533 (4.7) 95 (0.8) 214 (1.9)
Slovakia 304 260 (85.5) 36 (11.8) 1 (0.3) 5 (1.6) 1 (0.3) 1 (0.3)
Slovenia 150 123 (82.0) 16 (10.7) 0 (0.0) 4 (2.7) 0 (0.0) 7 (4.7)
Spain - - - - - - - - - - - - -
Sweden1 237 157 (66.2) 17 (7.2) 0 (0.0) 2 (0.8) 8 (3.4) 53 (22.4)
United Kingdom1 2,241 1,733 (77.3) 145 (6.5) 0 (0.0) 15 (0.7) 128 (5.7) 220 (9.8)
Total New cases 28,985 23,030 (79.5) 1,905 (6.6) 581 (2.0) 1,468 (5.1) 735 (2.5) 1,266 (4.4)
Retreatment cases  
Austria - - - - - - - - - - - - -
Belgium2 49 27 (55.1) 6 (12.2) 0 (0.0) 4 (8.2) 8 (16.3) 4 (8.2)
Bulgaria 146 52 (35.6) 38 (26.0) 2 (1.4) 23 (15.8) 27 (18.5) 4 (2.7)
Cyprus - - - - - - - - - - - - -
Czech Republic 44 30 (68.2) 7 (15.9) 0 (0.0) 4 (9.1) 2 (4.5) 1 (2.3)
Denmark2 18 8 (44.4) 3 (16.7) 0 (0.0) 1 (5.6) 1 (5.6) 5 (27.8)
Estonia 66 31 (47.0) 5 (7.6) 3 (4.5) 13 (19.7) 14 (21.2) 0 (0.0)
Finland 7 7 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
France - - - - - - - - - - - - -
Germany 178 114 (64.0) 25 (14.0) 3 (1.7) 8 (4.5) 13 (7.3) 15 (8.4)
Greece - - - - - - - - - - - - -
Hungary 130 51 (39.2) 26 (20.0) 26 (20.0) 12 (9.2) 13 (10.0) 2 (1.5)
Iceland 1 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (100.0)
Ireland2 28 16 (57.1) 4 (14.3) 0 (0.0) 0 (0.0) 3 (10.7) 5 (17.9)
Italy - - - - - - - - - - - - -
Latvia 167 96 (57.5) 14 (8.4) 2 (1.2) 17 (10.2) 36 (21.6) 2 (1.2)
Liechtenstein - - - - - - - - - - - - -
Lithuania 423 130 (30.7) 119 (28.1) 21 (5.0) 89 (21.0) 63 (14.9) 1 (0.2)24 www.eurosurveillance.org
Luxembourg - - - - - - - - - - - - -
Malta 1 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (100.0)
Netherlands2 40 27 (67.5) 3 (7.5) 0 (0.0) 1 (2.5) 0 (0.0) 9 (22.5)
Norway2 17 13 (76.5) 1 (5.9) 0 (0.0) 0 (0.0) 1 (5.9) 2 (11.8)
Poland 698 429 (61.5) 69 (9.9) 4 (0.6) 141 (20.2) 8 (1.1) 47 (6.7)
Portugal 182 140 (76.9) 13 (7.1) 0 (0.0) 11 (6.0) 12 (6.6) 6 (3.3)
Romania 4,933 2,462 (49.9) 479 (9.7) 683 (13.8) 767 (15.5) 325 (6.6) 217 (4.4)
Slovakia 42 35 (83.3) 1 (2.4) 1 (2.4) 1 (2.4) 4 (9.5) 0 (0.0)
Slovenia 13 10 (76.9) 3 (23.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Spain - - - - - - - - - - - - -
Sweden2 13 7 (53.8) 2 (15.4) 0 (0.0) 1 (7.7) 1 (7.7) 2 (15.4)
United Kingdom2 196 141 (71.9) 22 (11.2) 0 (0.0) 0 (0.0) 14 (7.1) 19 (9.7)
Total retreatment 7,392 3,826 (51.8) 840 (11.4) 745 (10.1) 1,093 (14.8) 545 (7.4) 343 (4.6)
Total for all 36,377 26,856 (73.8) 2,745 (7.5) 1,326 (3.6) 2,561 (7.0) 1,280 (3.5) 1,609 (4.4)
EEA: European Economic Area; EU: European Union.
1 Not previously diagnosed cases.
2 Previously diagnosed cases.
Table 2
Treatment outcome in culture-confirmed pulmonary TB cases by geographic origin and by country, EU/EEA countries, 
2007 (n=37,160)
  Cases Success Died Failed Defaulted Still on treatment
Transferred or 
unknown
Country N N (%) N (%) N (%) N (%) N (%) N (%)
National origin                          
Austria - - - - - - - - - - - - -
Belgium 327 224 (68.5) 42 (12.8) 0 (0.0) 14 (4.3) 8 (2.4) 39 (11.9)
Bulgaria 1,379 1,024 (74.2) 123 (8.9) 6 (0.4) 119 (8.6) 68 (4.9) 39 (2.8)
Cyprus - - - - - - - - - - - - -
Czech Republic 407 306 (75.2) 84 (20.6) 3 (0.7) 9 (2.2) 5 (1.2) 0 (0.0)
Denmark1 113 89 (78.8) 10 (8.8) 1 (0.9) 1 (0.9) 4 (3.5) 8 (7.1)
Estonia 312 184 (59.0) 38 (12.2) 3 (1.0) 36 (11.5) 51 (16.3) 0 (0.0)
Finland 146 99 (67.8) 35 (24.0) 1 (0.7) 1 (0.7) 5 (3.4) 5 (3.4)
France - - - - - - - - - - - - -
Germany 1,680 1,214 (72.3) 292 (17.4) 6 (0.4) 28 (1.7) 47 (2.8) 93 (5.5)
Greece - - - - - - - - - - - - -
Hungary 719 345 (48.0) 100 (13.9) 113 (15.7) 43 (6.0) 94 (13.1) 24 (3.3)
Iceland 1 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Ireland 149 103 (69.1) 14 (9.4) 0 (0.0) 3 (2.0) 2 (1.3) 27 (18.1)
Italy - - - - - - - - - - - - -
Latvia 887 691 (77.9) 66 (7.4) 3 (0.3) 44 (5.0) 82 (9.2) 1 (0.1)
Liechtenstein - - - - - - - - - - - - -
Lithuania 1,593 971 (61.0) 258 (16.2) 36 (2.3) 172 (10.8) 151 (9.5) 5 (0.3)
Luxembourg - - - - - - - - - - - - -
Malta 5 4 (80.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (20.0)
Netherlands 198 148 (74.7) 19 (9.6) 0 (0.0) 6 (3.0) 0 (0.0) 25 (12.6)
Norway 26 21 (80.8) 3 (11.5) 0 (0.0) 0 (0.0) 0 (0.0) 2 (7.7)
Poland 5,178 3,863 (74.6) 338 (6.5) 16 (0.3) 586 (11.3) 24 (0.5) 351 (6.8)
Portugal 1,622 1,397 (86.1) 93 (5.7) 5 (0.3) 48 (3.0) 56 (3.5) 23 (1.4)
Romania 16,178 11,970 (74.0) 932 (5.8) 1,125 (7.0) 1,300 (8.0) 420 (2.6) 431 (2.7)
Slovakia 346 296 (85.5) 38 (11.0) 2 (0.6) 6 (1.7) 4 (1.2) 0 (0.0)
Slovenia 128 106 (82.8) 17 (13.3) 0 (0.0) 4 (3.1) 0 (0.0) 1 (0.8)
Spain - - - - - - - - - - - - -
Sweden 66 37 (56.1) 12 (18.2) 0 (0.0) 1 (1.5) 1 (1.5) 15 (22.7)
United Kingdom 915 673 (73.6) 113 (12.3) 0 (0.0) 7 (0.8) 44 (4.8) 78 (8.5)25 www.eurosurveillance.org
Total Nationals 32,380 23,765 (73.4) 2,628 (8.1) 1,320 (4.1) 2,428 (7.5) 1,066 (3.3) 1,173 (3.6)
Foreign origin                          
Austria - - - - - - - - - - - - -
Belgium 288 190 (66.0) 17 (5.9) 0 (0.0) 39 (13.5) 13 (4.5) 29 (10.1)
Bulgaria 1 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Cyprus - - - - - - - - - - - - -
Czech Republic 96 55 (57.3) 9 (9.4) 1 (1.0) 27 (28.1) 1 (1.0) 3 (3.1)
Denmark2 118 88 (74.6) 4 (3.4) 1 (0.8) 3 (2.5) 8 (6.8) 14 (11.9)
Estonia 56 32 (57.1) 8 (14.3) 2 (3.6) 6 (10.7) 8 (14.3) 0 (0.0)
Finland 42 34 (81.0) 0 (0.0) 0 (0.0) 1 (2.4) 2 (4.8) 5 (11.9)
France - - - - - - - - - - - - -
Germany 1,157 914 (79.0) 66 (5.7) 1 (0.1) 24 (2.1) 37 (3.2) 115 (9.9)
Greece - - - - - - - - - - - - -
Hungary 24 14 (58.3) 0 (0.0) 3 (12.5) 4 (16.7) 3 (12.5) 0 (0.0)
Iceland 7 5 (71.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (28.6)
Ireland 95 62 (65.3) 3 (3.2) 0 (0.0) 0 (0.0) 9 (9.5) 21 (22.1)
Italy - - - - - - - - - - - - -
Latvia 52 39 (75.0) 2 (3.8) 0 (0.0) 5 (9.6) 5 (9.6) 1 (1.9)
Liechtenstein - - - - - - - - - - - - -
Lithuania 43 21 (48.8) 7 (16.3) 3 (7.0) 6 (14.0) 6 (14.0) 0 (0.0)
Luxembourg 18 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 18 (100.0)
Malta 9 5 (55.6) 0 (0.0) 0 (0.0) 1 (11.1) 1 (11.1) 2 (22.2)
Netherlands 285 216 (75.8) 10 (3.5) 0 (0.0) 4 (1.4) 0 (0.0) 55 (19.3)
Norway 121 90 (74.4) 2 (1.7) 0 (0.0) 0 (0.0) 5 (4.1) 24 (19.8)
Poland 22 10 (45.5) 0 (0.0) 0 (0.0) 3 (13.6) 0 (0.0) 9 (40.9)
Portugal 249 208 (83.5) 8 (3.2) 0 (0.0) 15 (6.0) 12 (4.8) 6 (2.4)
Romania 0 0 - 0 - 0 - 0 - 0 - 0 -
Slovakia 4 2 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (25.0) 1 (25.0)
Slovenia 35 27 (77.1) 2 (5.7) 0 (0.0) 0 (0.0) 0 (0.0) 6 (17.1)
Spain - - - - - - - - - - - - -
Sweden 184 127 (69.0) 7 (3.8) 0 (0.0) 2 (1.1) 8 (4.3) 40 (21.7)
United Kingdom 1,874 1,467 (78.3) 82 (4.4) 0 (0.0) 11 (0.6) 106 (5.7) 208 (11.1)
Total Foreigners 4,780 3,607 (75.5) 227 (4.7) 11 (0.2) 151 (3.2) 225 (4.7) 559 (11.7)
EEA: European Economic Area; EU: European Union.
1 Excluding native cases < 26 years old whose parents were born outside Denmark
2 Including native cases < 26 years old whose parents were born outside Denmark
Figure 2
Proportion of tuberculosis deaths by geographic origin, EU/EEA  countries1, 2007 (of n=37,160 cases)
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1 Excluding countries that did not or not in all years report cases.26 www.eurosurveillance.org
TB cases. The following case classification was used 
for the purpose of the analysis:
•	   A laboratory-confirmed TB case was a patient with 
culture-confirmed  disease  due  to  Mycobacterium 
tuberculosis complex. 
•	   A  new  case  was  any  case  who  had  not  received 
drug  treatment  for  active  TB  in  the  past,  or  who 
received anti-TB drugs for less than one month. 
•	   A retreatment case was a case diagnosed with TB 
in the past and who received treatment with anti-
TB drugs (excluding preventive therapy) for at least 
one month. 
•	   A pulmonary case was any case with TB affecting 
the lung parenchyma, the tracheo-bronchial tree or 
the larynx. 
•	   Multi-drug resistance was defined as resistance to 
at least isoniazid and rifampicin. 
•	   Foreign/national  origin  for  comparison  of  treat-
ment outcome by geographical origin of TB cases 
was classified according to place of birth: born in 
the  country  (national  origin)  or  born  outside  the 
country  (foreign  origin).  For  countries  reporting 
citizenship rather than place of birth, the former 
was used as a proxy of national/foreign origin. In 
Denmark,  the  place  of  birth  of  parents  was  also 
used to classify geographical origin. 
For  the  purpose  of  this  analysis,  internationally  rec-
ommended outcome categories where used with two 
additional categories [9]: ‘still on treatment’ after 12 
months of treatment, and ‘unknown’. Adopted defini-
tions in our study were:
•	   Cured:  The  treatment  has  been  completed  and 
culture has become negative on samples taken at 
the end of treatment and on at least one previous 
occasion. 
•	   Completed:  The  treatment  has  been  completed 
but the case does not meet the criteria for cure or 
treatment failure. 
•	   Failed: Culture or sputum smear remain positive or 
become positive again five months or later into the 
course of treatment. 
•	   Died: Death, irrespective of cause, occurred before 
the patient was cured or treatment was completed. 
•	   Defaulted: The treatment was interrupted for two 
months or more, not resulting from a decision of 
the care provider; or the patient was lost to follow-
up for two months or more before the end of treat-
ment, except if transferred. 
•	   Transferred:  The  patient  was  referred  to  another 
clinical unit for treatment, and information on out-
come is not available. 
•	   Still on treatment: The patient is still on treatment 
at 12 (24 when applicable) months after the start 
of treatment and did not meet any other outcome 
during treatment. This category includes patients 
whose initial treatment was changed due to poly-
resistance (i.e. resistance to at least two first-line 
drugs) of the isolate taken at the start of treatment, 
whose  treatment  was  prolonged  because  of  side 
effects/complications,  whose  initial  regimen  had 
been planned for more than 12 months, or patients 
for whom information on the reasons for being still 
on treatment was not available. 
•	   Unknown: Information on outcome is not available, 
for cases not known to have been transferred. 
•	   Success:  This  refers  to  the  combined  number  of 
patients  belonging  to  the  treatment  categories 
‘cured’  and  ‘completed’.  The  success  rate  target 
(established by the WHA as 85% of new smear-pos-
itive cases) has been adapted to the EU/EEA set-
ting  where  bacteriological  confirmation  of  cases 
is done by culture. Thus for the purposes of this 
study, a success rate target of 85% applies to new 
laboratory-confirmed cases. 
•	   Cohort: This includes all cases eligible for outcome 
analysis  (cohorts);  i.e.  all  the  culture-confirmed 
pulmonary TB cases notified in the calendar year 
of interest, after exclusion of cases with final diag-
nosis other than TB. 
For the purpose of calculating the outcome variables, 
culture-confirmed pulmonary TB cases notified in the 
calendar year of interest were used as denominators. 
Data for one country were considered to be complete 
if the cohorts used as denominators included all cul-
ture-confirmed  pulmonary  TB  cases  notified  in  the 
year  selected  for  analysis  and  if  the  combined  total 
of ‘defaulted, transferred and unknown’ cases did not 
exceed 35% of cases notified in that year. 
Proportions of deaths by geographic origin were strati-
fied by age to allow comparability.
Adjustments  to  account  for  how  countries  with  high 
numbers of cases influence the EU/EEA average were 
not performed as the study aimed at presenting overall 
figures for EU/EEA patients.
Figure 3
Age-stratified case fatality by geographic origin, EU/EEA 
countries, 2007 (of n=25,391 cases)
EEA: European Economic Area; EU: European Union.
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Results
Twenty-two countries reported TOM data at 12 months 
for  culture-confirmed  pulmonary  TB  cases  reported 
in 2007. Data were considered to be complete as per 
study definition in all reporting countries. The overall 
treatment  success  rate  for  all  laboratory-confirmed 
pulmonary cases was 73.8%. Of these patients, 7.5% 
died while being treated for TB, 3.6% failed treatment, 
7.0% defaulted, 3.5% were still on treatment at the end 
of the 12-month observation period and 4,4% had an 
outcome recorded as unknown or transferred (Figure 1, 
Table 1).
Among  new  laboratory-confirmed  pulmonary  cases, 
79.5% had a successful outcome, 6.6% died, 2% failed, 
2.5%  were  still  on  treatment,  and  4.4%  were  trans-
ferred or had an unknown outcome (Table 1). Among 
countries  with  more  than  20  new  culture-confirmed 
pulmonary  cases,  success  rates  varied  widely  from 
50.8% in Hungary to 86.6% and 85.5% in Portugal and 
Slovakia respectively. Three countries achieved treat-
ment success in 85% or more of this category of cases: 
Iceland, 85.7%, Portugal, 86.6% and Slovakia, 85.5%. 
The percentage of cases that died while undergoing TB 
treatment ranged from 1.8% in Norway to 18.7% in the 
Czech Republic. Overall treatment success rates below 
75%  were  associated  with  a  high  loss  to  follow-up 
(defaulted and transferred or unknown) ranging from 
6.6% to 25.7%.
Treatment outcomes for retreatment culture-confirmed 
pulmonary  TB  cases  were  reported  from  22  EU/EEA 
Member States (Table 1). For seven countries, informa-
tion  about  previous  treatment  was  not  distinguished 
and reported as previously diagnosed cases (Belgium, 
Denmark,  Ireland,  the  Netherlands,  Norway,  Sweden 
and United Kingdom). Among these retreatment cases 
the  overall  success  rate  was  lower  (51.8%;  range: 
0%–100%)  than  among  new  cases.  Death  (11.4%), 
treatment failure (10.1%), default (14.8%) and still on 
treatment  (7.4%)  were  more  frequently  reported  in 
this group than among new cases. Only six countries 
achieved a treatment success of at least 70% among 
retreatment cases (Table 1).
Analysis of data by geographic origin revealed similar 
proportions  of  successfully  treated  cases  of  national 
origin  (73.4%)  and  those  of  foreign  origin  (75.5%). 
However,  marked  differences  were  observed  in  the 
proportion of deaths, with higher percentages among 
cases of national origin (8.1%) compared with those of 
foreign origin (4.7%). Similarly, differences were found 
in the percentages of failed cases (4.1% in nationals 
versus 0.2% in cases of foreign origin) and transferred/
unknown (3.6% in nationals versus 11.7% in cases of 
foreign origin) (Table 2, Figure 2).
With regards to the differences in proportion of deaths 
between foreign origin and national cases, the stratifi-
cation of case fatality by age group (Figure 3) reveals 
that  age  acts  as  an  effect  modifier,  where  the  pro-
portion of deaths increased with increasing age. The 
highest  case  fatality  was  in  the  age  group  of  over 
64-year-olds,  regardless  of  geographical  origin.  The 
high case fatality in 0-4-year-old children in the group 
of foreign origin is a doubtful interpretation as there 
was only one death in this group.
Fifteen countries (12 of which provided complete data 
as  per  study  definition)  reported  the  treatment  out-
come at 24 months for culture-confirmed MDR TB cases 
(new and retreatment). The overall treatment success 
in the 15 countries ranged from 19.8% to 100%. Of the 
entire  cohort,  16.6%  died  while  on  treatment,  17.0% 
failed treatment and 13.2% defaulted. 17.0% of regis-
tered cases were still on treatment at the end of the 24 
months observation period and 5.3% had been trans-
ferred or had an unknown outcome (Table 3).
Analysis of trends for the cohorts 2003 to 2007 did not 
reveal any significant difference in the proportions of 
cases belonging to any of the treatment outcome cat-
egories.  Treatment  success  remained  in  the  range  of 
78% to 80% in the new laboratory-confirmed pulmo-
nary cases. Minimal improvement from 48% to 52.2% 
was  recorded  between  the  2006  and  2007  cohorts 
of  retreatment  culture-confirmed  pulmonary  cases 
(Figure 1).
Discussion and conclusions
This analysis of treatment outcome monitoring within 
the  EU  and  EEA  Member  States  revealed  significant 
findings concerning TB control in the region. Firstly, it 
is a matter of concern that there has been only a mar-
ginal improvement in the number of countries report-
ing  treatment  outcomes  to  the  EU-wide  database, 
which increased by only one Member State compared 
with  the  2006  cohort  reporting  (22  versus  21  coun-
tries). Similarly, the number of cases with an unknown 
treatment  outcome  because  of  transfer  or  ‘outcome 
unknown’, remained high with an average of 4.4% of 
all  pulmonary  culture-confirmed  cases  belonging  to 
this  category  and  with  six  of  22  countries  reporting 
more than 10% of unknown outcomes. This represents 
a programmatic weakness in one of the pillars of TB 
control and highlights the importance of the monitor-
ing and evaluation process [2,3,10].
More disturbing is the fact that there has been no sig-
nificant improvement in the percentage of cases suc-
cessfully treated over the past five years, with 79.5% of 
new  laboratory-confirmed  pulmonary  cases  success-
fully treated and 51.8% in retreatment cases. This is 
reflected at the level of the individual Member States: 
only three countries achieved the target of 85% suc-
cess rate in 2007 compared with seven countries for 
the 2006 cohort.
The authors would have wished to extend the analy-
sis of completeness of treatment to all notified cases 
to gain further insight in the distribution and quality 
of outcomes; however data proved insufficient to pro-28 www.eurosurveillance.org
ceed with this approach since only few countries report 
treatment completion for all cases.
Achieving  high  success  rates  becomes  particularly 
important in a setting like the EU and EEA where the 
decline in incidence that was typical of the past few 
decades is becoming slower in most countries [2]. This 
trend is certainly influenced by many factors including 
importation of cases from high-burden countries, out-
breaks among vulnerable populations, persisting MDR 
TB, and in some cases a lack of adequate TB control 
measures. In this setting it is essential to achieve opti-
mal treatment success in all TB patients.
The need for reaching the success rate target is justified 
by its potential epidemiological impact. Several epide-
miological  models  have  shown  [11-14]  that  achieving 
the 85% success target coupled with a case detection 
of at least 70% would cause a decline in the annual TB 
incidence rate of 5-10% in the absence of co-infection 
with human immunodeficiency virus (HIV). These theo-
retical assumptions are further corroborated by empiri-
cal  findings,  particularly  in  the  European  context.  In 
fact,  the  TB  incidence  has  been  declining  rapidly  all 
over Europe over the past century, but the decline has 
more than doubled following the introduction of effec-
tive treatment. 
The analysis of the data by geographical origin (national 
versus foreign) revealed a similarity in the two groups 
in  terms  of  overall  success  rate.  Differences  exist  in 
the  distribution  of  negative  outcomes  with  regard  to 
geographic  origin.  However,  stratifying  case  fatality 
by age showed that the excess proportion of deaths 
Table 3
Treatment outcome of multidrug-resistant tuberculosis cases after 24 months of treatment, EU/EEA countries, 2006 cohort 
(n=1,190)
Country
Total number of 
MDR cases
TOM after 24 months
Success Died Failed Defaulted
Still on treat-
ment
Transferred or 
unknown
N % N % N % N % N % N %
Austria - - - - - - - - - - - - -
Belgium 18 10 (55.6) 1 (5.6) 0 (0.0) 0 (0.0) 3 (16.7) 4 (22.2)
Bulgaria - - - - - - - - - - - - -
Cyprus 0 - - - - - - - - - - - -
Czech Republic 12 3 (25.0) 4 (33.3) 0 (0.0) 3 (25.0) 2 (16.7) 0 (0.0)
Denmark 3 2 (66.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (33.3) 0 (0.0)
Estonia 53 24 (45.3) 12 (22.6) 2 (3.8) 14 (26.4) 1 (1.9) 0 (0.0)
Finland - - - - - - - - - - - - -
France - - - - - - - - - - - - -
Germany 83 42 (50.6) 4 (4.8) 1 (1.2) 10 (12.0) 14 (16.9) 12 (14.5)
Greece - - - - - - - - - - - - -
Hungary 17 9 (52.9) 1 (5.9) 5 (29.4) 1 (5.9) 1 (5.9) 0 (0.0)
Iceland 0 - - - - - - - - - - - -
Ireland 4 1 (25.0) 0 (0.0) 0 (0.0) 1 (25.0) 0 (0.0) 2 (50.0)
Italy - - - - - - - - - - - - -
Latvia 142 87 (61.3) 34 (23.9) 6 (4.2) 15 (10.6) 0 (0.0) 0 (0.0)
Liechtenstein - - - - - - - - - - - - -
Lithuania - - - - - - - - - - - - -
Luxembourg 0 - - - - - - - - - - - -
Malta 2 2 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Netherlands - - - - - - - - - - - - -
Norway 3 1 (33.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (66.7)
Poland 32 11 (34.4) 4 (12.5) 3 (9.4) 4 (12.5) 0 (0.0) 10 (31.3)
Portugal 25 16 (64.0) 6 (24.0) 1 (4.0) 2 (8.0) 0 (0.0) 0 (0.0)
Romania 788 156 (19.8) 130 (16.5) 184 (23.4) 107 (13.6) 178 (22.6) 33 (4.2)
Slovakia 7 3 (42.9) 2 (28.6) 0 (0.0) 0 (0.0) 2 (28.6) 0 (0.0)
Slovenia 1 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Spain - - - - - - - - - - - - -
Sweden - - - - - - - - - - - - -
United Kingdom - - - - - - - - - - - - -
Subtotal EU/EEA 1,190 368 (30.9) 198 (16.6) 202 (17.0) 157 (13.2) 202 (17.0) 63 (5.3)
EEA: European Economic Area; EU: European Union; MDR: multidrug-resistant; TOM: treatment outcome monitoring.29 www.eurosurveillance.org
among  nationals  was  attributed  to  older  age.  These 
findings  are  not  unexpected,  and  the  similarities  in 
terms  of  success  rate,  evident  also  at  country  level, 
seem to suggest that foreign-born patients are not at a 
higher risk of unfavourable outcome.
The analysis also revealed a potential for worsening of 
the M/XDR TB epidemic in the EU and EEA, resulting 
from  the  high  default  rates  recorded  among  retreat-
ment  and  MDR  TB  cases  (14.8%  and  13.2%,  respec-
tively). Despite the data limitations with respect to the 
MDR TB analysis (with regards to data representative-
ness completeness and quality assurance of laboratory 
methods) a clear need for strengthening case holding 
and  treatment  monitoring  among  these  two  popula-
tions  (retreatment  and  MDR  TB)  emerges.  As  widely 
shown in the literature, defaulting and previous unsuc-
cessful treatment represent the biggest risk factor for 
the emergence of drug resistance, in particular M/XDR 
TB [15-18].
The role that surveillance of TB treatment outcomes can 
and ought to play in strengthening TB control needs to 
be  highlighted.  Reporting  of  outcomes  allows  close 
monitoring of the ability of TB programmes to support 
and ensure completion of patients’ treatment. It also 
allows  tailoring  control  activities  to  high-risk  groups 
defined in terms of their inability to comply with treat-
ment and achieve successful outcomes.
The  claim  that  an  unknown  or  unreported  treatment 
outcome does not necessarily represent a negative one 
should be balanced against the argument that lack of 
knowledge about treatment outcomes deprives the pro-
gramme of essential information to guide TB control.
Finally  it  should  be  noted  that  the  importance  of 
achieving the highest possible treatment success rate 
goes  beyond  its  programmatic  and  epidemiological 
impact.  Achieving  universal  success  in  treating  indi-
vidual  patients  remains  a  fundamental  point  in  case 
management and patient care.
The importance of treatment outcome monitoring needs 
to  be  further  stressed  and  mechanisms  explored  to 
maximise progress towards achievement of the targets. 
Clinicians,  public  health  experts  and  policy  makers 
must be convinced of the importance of a standardised 
approach to monitoring of treatment including a proper 
evaluation of its implementation. Only by recognising 
the  key  position  that  treatment  outcome  monitoring 
holds in TB control can progress towards elimination 
be pursued.
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To  quantify  the  risk  of  developing  tuberculosis  (TB) 
following  school  contact  with  a  student  with  smear 
positive  respiratory  TB  in  a  population  with  a  high 
background  rate  of  tuberculosis,  a  retrospective 
cohort study was conducted. This study included all 
students and staff (n=1,065) at an inner city second-
ary school in Birmingham, United Kingdom (UK). Being 
in  the  same  school  year  as  the  index  case  resulted 
in a significantly higher risk of being diagnosed with 
active  TB  (odds  ratio  (OR)  6.11)  and  either  active  or 
latent  TB  (OR  10.52)  compared  to  the  risk  for  pupils 
in other school years. Neither lower level classroom 
exposure in tutoring groups nor being a staff member 
resulted  in  significantly  increased  risk  of  infection. 
The number of cases detected in the school was signif-
icantly higher than compared with the TB notification 
rate for the respective age groups in the population in 
the area. This study is consistent with the small body 
of evidence that already exists suggesting that greater 
levels of classroom contact with a student with smear 
positive  active  TB  significantly  increases  the  risk  of 
contracting active and latent TB. It also suggests that 
staff may be at a lower risk of active TB than students. 
It does not appear that being in an area with high TB 
incidence substantially alters the epidemiology of the 
outbreak or risk of transmission between students in 
comparison to other populations.
Introduction 
Historically tuberculosis (TB) has been a major cause of 
premature death in the United Kingdom (UK). It remains 
a serious disease and active TB can lead to death if not 
treated.  An  outbreak  of  TB  in  a  school  often  causes 
major concern for children and parents and generates 
significant volumes of work for health-care organisa-
tions. In these situations it is important that action is 
based on robust scientific evidence to ensure that the 
correct response is being applied. However, the current 
evidence base for the management of a school-based 
outbreak of TB is small and increasing the size of this 
will ensure that screening strategies are both safe and 
effective in identifying those with infection. 
The evidence base for the United Kingdom’s National 
Institute for Health and Clinical Excellence (NICE) rec-
ommendations  for  management  of  TB  in  schools  [1] 
refers to five analytical studies [2-6] none of which are 
UK based, nor conducted in areas of high local preva-
lence of TB or where the majority of students are from 
black or minority ethnic (BME) groups. Of these studies 
only three have provided estimates of the relative risk 
to children and staff within the school following a case 
of smear positive (open) TB in a school pupil. 
We conducted a retrospective cohort study following a 
large school-based TB outbreak in a state funded sec-
ondary school in the inner city of Birmingham, UK. Over 
95% of the school’s students were from BME groups 
and all were aged 10-16 years. The school was located 
in an area of central Birmingham with a high propor-
tion of residents from a BME group (68%) [7] and one 
of highest incidence rates of tuberculosis in England 
[8]. In 2006 and 2007 it had a direct standardised inci-
dence rate for TB of 109.6 and 99.4 cases per 100,000 
population,  respectively  [9]  compared  with  the  UK 
average of 13.8 per 100,000 [10]. In both the 10-14 and 
15-19-year-old age groups in the school uptake area the 
TB incidence was 105.7 per 100,000 in 2007 [8]. 
The index case for the outbreak was a 16-year-old male 
who was diagnosed with smear positive respiratory TB 
in  December  2008.  He  had  been  increasingly  unwell 
with cough and weight loss since September 2008. He 
had attended the school as usual for the majority of 
this time after which he received antimicrobial therapy 
and became smear negative. Initially the students in 
the same school year as the index case were screened 
for TB in February 2009. As a result of this screening 
which  yielded  several  secondary  cases  of  active  TB, 
the  whole  school  population  was  offered  screening 
as advised by national guidance [1]. Screening of the 
whole school was carried out in April 2009.31 www.eurosurveillance.org
This study aims to:
•	   Identify  the  risks  of  developing  tuberculosis  fol-
lowing  different  types  of  school  contact  with  a 
child with smear positive respiratory TB. 
•	   Quantify the magnitude of these risks. 
Methods 
Study population
The  study  population  comprised  all  students  (886) 
and  staff  members  (179)  who  attended  or  worked  at 
the school between September 2008 and April 2009 
(n=1,065).  The  student  population  was  evenly  split 
between  five  school  years  (173-189  pupils  in  each 
year). Students in the same school year were all of a 
similar age. 
Outcome measures and case ascertainment
The  primary  outcome  measure  was  the  diagnosis  of 
active  TB  infection  requiring  full  antimicrobial  treat-
ment by a physician specialising in infectious or respi-
ratory diseases. The secondary outcome measure was 
the diagnosis of active or latent TB requiring chemo-
prophylaxis according to local TB screening protocols. 
Students  were  screened  by  Mantoux  testing.  All  stu-
dents  with  a  positive  Mantoux  result  (greater  than 
15  mm  if  Bacillus  Calmette-Guérin  (BCG)  vaccinated, 
greater than 5 mm if unvaccinated) were referred for 
further clinical assessment. All staff were over 18 years 
of age and were offered screening by chest radiograph 
or Mantoux testing if pregnant. All staff with an abnor-
mal chest radiograph or a positive Mantoux result were 
referred for clinical assessment. 
All  patients  referred  were  assessed  for  TB  infection 
by at least clinical history, clinical examination, chest 
radiograph  and  gamma  interferon  test  (T-spot),  plus 
microscopic examination of sputum if coughing. More 
invasive diagnostic testing was carried out as clinically 
indicated.  Diagnosis  of  latent  or  active  tuberculosis 
was made by a consultant respiratory physician. 
Measurement of exposure 
Data  were  collected  for  each  subject  during  the  co-
ordinated  health  service  response  to  the  outbreak, 
including information on date of birth, address, history 
of BCG vaccination and for students, school year and 
tutoring group. 
Students  from  different  school  years  did  not  mix  for 
lessons but there was significant mixing of students 
within  a  school  year  for  lessons.  Class  sizes  varied 
from  approximately  20-35  students.  The  only  formal 
mixing of students between years was as part of a tutor 
Table 2
Results of logistic regression analysis of exposure factors to the risk of being diagnosed with active or latent tuberculosis, 
United Kingdom, 2009 
Risk of being diagnosed with active tuberculosis
Exposure Odds ratio 95% Confidence interval p-value
Staff member (versus pupil) 0 0 0.99
Male 0.89 0.28-2.84 0.85
Previous BCG vaccination 2.83 0.36-22.09 0.32
Same tutor group as index case 0 0 0.99
Same school year as index case  6.11 1.91-19.48 0.002
Risk of being diagnosed with active or latent tuberculosis
Exposure Odds ratio 95% Confidence interval p-value
Staff member (versus pupil) 0 0 0.99
Male 1.12 0.68-1.85 0.66
Previous BCG vaccination 1.32 0.68-2.58 0.41
Same tutor group as index case 0.71 0.09-5.45 0.75
Same school year as index case  10.52 6.14-18.03 <0.0001
BCG: Bacillus Calmette-Guérin
Table 1
Outcomes of tuberculosis exposure groups under study, United Kingdom, 2009 (n=1,065)
Pupils Staff
Same school year as 
index case
Other school year Same tutor group as index case Other tutor group
Active tuberculosis 12 0 7 5 0 12
Latent tuberculosis 55 0 37 18 1 54
No evidence of tuberculosis 698 172 103 595 15 683
Did not attend screening 121 7 23 98 2 119
Total 886 179 170 716 18 86832 www.eurosurveillance.org
group where a total of 18 students from different years 
shared a classroom weekly for 1.5 hours per week. 
For  students,  two  measures  of  increased  exposure 
were  used;  being  in  the  same  school  year  with  the 
index  case  (three  30  hours  of  classroom  exposure 
per week) and being in the same tutoring group (tutor 
groups included students from all school years, shar-
ing  a  tutoring  group  equated  to  1.5  hours  classroom 
exposure  per  week).  Students  not  in  the  same  tutor 
group  or  school  year  were  classified  as  having  low 
school  exposure  (less  than  1.5  hours  per  week).  For 
staff substantial exposure was defined as those who 
had prolonged and direct contact with the index case. 
This exposure was assessed clinically by interview as 
part of a risk assessment for each staff member.
Statistical analysis
Standard  descriptive  statistics  were  used  to  sum-
marise  the  data.  The  relationship  between  exposure 
and outcomes was analysed using logistic regression 
which allowed the effect of interactions between expo-
sure categories on outcomes to be assessed. Reported 
p-values  are  all  two-sided.  Except  where  stated  oth-
erwise,  the  control  group  was  all  students  classi-
fied as the low exposure group. Comparisons of risk 
were made with (i) those in the same school year as 
the index case, and (ii) those in the same tutor group 
as the index case and staff. The chi-square test was 
used to assess differences in the rate of TB infection 
between  the  school  population  and  the  overall  rate 
seen in school uptake area population [8] All analysis 
was carried out using SPSS version 15. 
Results
All students at the school were aged between 10 and 
16 years at the time of investigation, all of which were 
included in the study.  The study also included all staff 
members  employed  at  the  school  during  the  study 
period. 
All  students  and  staff  were  offered  screening.  Staff 
numbered 179 and of these 172 participated (96.1%). 
There were 886 students and of these 765 (86.3%) par-
ticipated.  The  remainder,  121  pupils  and  seven  staff, 
declined  screening.  Complete  data  are  available  for 
all participants. The outcomes for the different groups 
under study are presented in Table 1.
Being  in  the  same  school  year  as  the  index  case 
resulted in a significantly higher risk of having active 
TB (OR 6.11) and either active or latent TB (OR 10.52) 
(Table  2).  The  lower  level  of  classroom  exposure  of 
those  attending  the  same  tutoring  groups  did  not 
result in any significantly increased risk. No staff mem-
ber was diagnosed with active or latent TB.
Previous BCG vaccination did not significantly reduce 
the risk of being diagnosed with active or latent TB. 
Multiple  logistic  regression  analysis  showed  no  sig-
nificant  interaction  between  exposure  categories  on 
outcomes.
Applying  the  age  specific  rate  of  TB  infection  of  the 
school uptake area population [8] to the school popu-
lation it would be expected that there would be 0.94 
cases  of  TB  diagnosed  per  year.  This  is  significantly 
lower  than  the  actual  number  seen  in  our  outbreak 
investigation (chi-square p=0.002).
Discussion
The study supports current recommendations for man-
agement of TB cases in schools. The highest level of 
risk  of  being  diagnosed  with  active  or  latent  TB  and 
therefore  priority  area  of  concern  is  children  in  the 
same  school  year  as  the  index  case.  The  increased 
level of exposure seen in other groups did not trans-
late to substantially increased risk of infection. While 
we  would  not  suggest  that  teachers  with  substantial 
levels of exposure should not be tested for TB in school 
based  outbreaks,  these  results  suggest  they  can  be 
reassured they are unlikely to be at higher levels of risk 
for contracting active TB. 
It is possible that the high numbers of students diag-
nosed  with  active  TB  in  our  study  were  due  to  the 
high  incidence  rate  in  the  population.  However,  the 
large and significant difference between the expected 
number of cases in the school and the number actu-
ally  found  makes  it  unlikely  that  the  majority  of 
cases  detected  by  screening  were  due  to  previously 
undiagnosed  TB  acquired  in  the  wider  community. 
In  addition,  three  cases  with  active  TB  had  their 
Mycobacterium tuberculosis strains molecularly typed 
by DNA fingerprinting. All of them were indistinguish-
able from one another and identical to the strain found 
in the index case which strongly supports the school 
being the place of transmission.
This study adds to the small evidence base related to 
school  based  TB  outbreaks.  A  particular  strength  of 
the study is the size of the population, which is larger 
than most of the other published studies [2,3,6] and 
the relatively low proportion of the population that did 
not attend screening which increases the reliability of 
the results.
The most significant limitation of this study is the sole 
use of chest radiograph in the screening of non-preg-
nant staff members. UK guidance recommends that this 
is satisfactory for those aged over 35 years and have 
had previous BCG vaccination [1]. However, those that 
do not satisfy these criteria should ideally be screened 
by Mantoux testing. Due to the limitation of the data 
available  we  were  unable  to  estimate  what  propor-
tion of staff should ideally have had Mantoux testing. 
Therefore  caution  should  be  used  when  interpreting 
the  prevalence  of  latent  TB  in  the  staff  population. 
However, the results for the prevalence of active TB in 
the staff group should still be reliable since all subjects 33 www.eurosurveillance.org
had either normal chest radiographs or TB excluded by 
a physician if the radiograph was abnormal.
Current NICE guidance quotes a relative risk for existing 
high school pupils compared to new school entrants of 
2.3 (95% CI 1.7-3.2) [3]. Only two other studies exam-
ined the risk of classroom versus non-classroom expo-
sure (relative risk (RR) 2.3 95% CI 1.4-3.8) [2], (RR 10.9 
95% CI 8.7-13.4) [4]. We have reported OR because of 
the  use  of  logistic  regression  and  although  not  the 
same  as  RR  their  values  become  increasingly  similar 
as the ratio of subjects without disease to those with 
disease  increases  above  6:1.  This  study’s  main  find-
ing  of  the  risk  of  students  in  the  same  school  year 
developing active TB has a ratio of approximately 24:1. 
Therefore we can be confident that the values of the 
OR presented here can be directly compared to the RR 
reported in previous studies without the need for sta-
tistical correction.
A number of other papers have discussed the epidemi-
ology of school outbreaks but have not formally quan-
tified risk. No studies were found that quantified the 
risk to staff of contracting TB from students although 
studies exist that examined risks to students taught by 
staff with open TB [11]. 
The results of this study are consistent with other stud-
ies published on school-based TB outbreaks and con-
firm that higher levels of classroom exposure to people 
with  open  TB  significantly  increase  the  risk  of  being 
diagnosed  with  active  or  latent  TB.  It  also  suggests 
that the risk to staff may be very small when teaching 
children who have open TB although more research is 
required to confirm this. It does not appear that being 
in an area of high background TB incidence substan-
tially alters the epidemiology of the outbreak or risk of 
transmission between students in comparison to other 
populations and that there is no evidence that alterna-
tive screening strategies are required in this situation.
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